{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "331689d5",
   "metadata": {},
   "outputs": [
    {
     "ename": "",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31mThe kernel failed to start as the Python Environment 'venv (Python 3.11.13)' is no longer available. Consider selecting another kernel or refreshing the list of Python Environments."
     ]
    }
   ],
   "source": [
    "import json\n",
    "import logging\n",
    "import os\n",
    "import time\n",
    "import asyncio\n",
    "import re\n",
    "from typing import Dict, List, Any, Optional, Tuple, Union\n",
    "from pathlib import Path\n",
    "from datetime import datetime\n",
    "import traceback\n",
    "import warnings\n",
    "\n",
    "import google.generativeai as genai\n",
    "from google.genai import types\n",
    "\n",
    "import fitz\n",
    "import PyPDF2\n",
    "\n",
    "import httpx\n",
    "\n",
    "from pydantic import BaseModel, Field, validator\n",
    "from pydantic.types import constr, conint\n",
    "\n",
    "import pathlib\n",
    "import shutil\n",
    "from io import BytesIO\n",
    "\n",
    "logging.basicConfig(\n",
    "    level=logging.INFO,\n",
    "    format='%(asctime)s - %(levelname)s - %(name)s - %(message)s'\n",
    ")\n",
    "logger = logging.getLogger(__name__)\n",
    "\n",
    "warnings.filterwarnings(\"ignore\", category=UserWarning)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "4a59210b",
   "metadata": {},
   "outputs": [],
   "source": [
    "from dotenv import load_dotenv\n",
    "load_dotenv()  \n",
    "\n",
    "api_key = os.getenv('GEMINI_API_KEY')\n",
    "genai.configure(api_key=api_key)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "07fde714",
   "metadata": {},
   "source": [
    "# PA DATA"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "677e8bb9",
   "metadata": {},
   "outputs": [],
   "source": [
    "def extract_fields_with_positions(pdf_path):\n",
    "   doc = fitz.open(pdf_path)\n",
    "   fields = []\n",
    "   for page_num, page in enumerate(doc, start=1):\n",
    "       for w in page.widgets() or []:\n",
    "           field = {\n",
    "               \"name\": w.field_name,\n",
    "               \"type\": \"checkbox\" if w.field_type == fitz.PDF_WIDGET_TYPE_CHECKBOX else \"text\",\n",
    "               \"value\": w.field_value,\n",
    "               \"page\": page_num,\n",
    "               \"field_type\": w.field_type,\n",
    "               \"field_type_string\": w.field_type_string,\n",
    "               \"field_label\": w.field_label,\n",
    "           }\n",
    "           fields.append(field)\n",
    "\n",
    "   # Group fields by page\n",
    "   fields_by_page = {}\n",
    "   for field in fields:\n",
    "       page_num = field['page']\n",
    "       if page_num not in fields_by_page:\n",
    "           fields_by_page[page_num] = []\n",
    "       fields_by_page[page_num].append(field)\n",
    "   \n",
    "   return fields_by_page"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "cb9976cc",
   "metadata": {},
   "outputs": [],
   "source": [
    "abdulla_pa_fields = extract_fields_with_positions(\"Input Data/Abdulla/PA.pdf\")\n",
    "abdulla_pa_fields"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "3b8f9b15",
   "metadata": {},
   "outputs": [],
   "source": [
    "PROMPT_PA = \"\"\"You are an expert medical document processing assistant specializing in Prior Authorization (PA) form analysis and field mapping. Your task is to process and enrich PA form field data with detailed contextual information.\n",
    "\n",
    "Given Input:\n",
    "1. A structured dataset containing PA form field definitions including:\n",
    "   - Field names (e.g. CB1, T1)\n",
    "   - Field types (checkbox, text, etc.)\n",
    "   - Page numbers\n",
    "   - Field labels\n",
    "   - Current values\n",
    "\n",
    "2. The complete Prior Authorization form PDF document\n",
    "\n",
    "Required Processing:\n",
    "For each form field, analyze sequentially by page number and:\n",
    "\n",
    "1. Extract the implicit question being asked by the field\n",
    "   - For checkboxes: Frame the label as a yes/no question\n",
    "   - For text fields: Frame as an information request\n",
    "   - For dates: Specify what event/action the date refers to\n",
    "\n",
    "2. Generate rich contextual information that includes:\n",
    "   - The section/category the field belongs to\n",
    "   - Whether it's a primary question or sub-question\n",
    "   - Whose information is being requested (patient, provider, insurer)\n",
    "   - Any dependencies on other fields\n",
    "   - Clinical relevance of the requested information\n",
    "\n",
    "<CRITICAL_REQUIREMENTS>\n",
    "- Every field must have both question and context added\n",
    "- Context must be specific and clinically relevant\n",
    "- Maintain logical relationships between fields\n",
    "- Preserve exact field names and labels\n",
    "- Keep context concise but informative (25 words max)\n",
    "- Only output valid JSON\n",
    "</CRITICAL_REQUIREMENTS>\n",
    "\n",
    "<RESPONSE_FORMAT>\n",
    "Each output JSON object should only contain the fields - name, type, page, field_label, question, context in the following format:\n",
    "{{\"name\": \"CB1\",\n",
    " \"type\": \"checkbox\",\n",
    " \"page\": 2,\n",
    " \"field_label\": \"Start of treatment\",\n",
    " \"question\": \"Is this a new treatment start for the patient?\",\n",
    " \"context\": \"Initial checkbox in treatment timeline section indicating whether patient is beginning new therapy versus continuing existing treatment.\"}}\n",
    "{{\"name\": \"T2\",\n",
    " \"type\": \"text\", \n",
    " \"page\": 2,\n",
    " \"field_label\": \"Start date: (MM)\",\n",
    " \"question\": \"What is the month of treatment start?\",\n",
    " \"context\": \"2-digit month format for planned medication initiation date in treatment scheduling section.\"}}\n",
    "</RESPONSE_FORMAT>\n",
    "\n",
    "<PA_FORM_DATA>\n",
    "{page_fields}\n",
    "</PA_FORM_DATA>\n",
    "\n",
    "Return valid JSON array only. No explanations outside the JSON.\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "6ef0ddc5",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Page 2 processed\n",
      "Page 3 processed\n",
      "Page 4 processed\n",
      "Page 5 processed\n"
     ]
    }
   ],
   "source": [
    "async def query_gemini_async(prompt, pdf_path, model=\"gemini-2.5-flash\"):\n",
    "    import pathlib\n",
    "    \n",
    "    filepath = pathlib.Path(pdf_path)\n",
    "    loop = asyncio.get_event_loop()\n",
    "    \n",
    "    # Configure model for JSON output\n",
    "    generation_config = genai.GenerationConfig(\n",
    "        response_mime_type=\"application/json\"\n",
    "    )\n",
    "    \n",
    "    response = await loop.run_in_executor(\n",
    "        None,\n",
    "        lambda: genai.GenerativeModel(\n",
    "            model,\n",
    "            generation_config=generation_config\n",
    "        ).generate_content([\n",
    "            genai.upload_file(path=filepath),\n",
    "            prompt\n",
    "        ])\n",
    "    )\n",
    "    \n",
    "    return response.text\n",
    "\n",
    "async def process_pa_fields_async(pa_fields_data, pdf_path):\n",
    "    async def process_page(page_num, page_fields):\n",
    "        prompt = PROMPT_PA.format(page_fields=json.dumps(page_fields))\n",
    "        result = await query_gemini_async(prompt, pdf_path)\n",
    "        return page_num, result\n",
    "    \n",
    "    # Create tasks for all pages\n",
    "    tasks = [process_page(page, fields) for page, fields in pa_fields_data.items()]\n",
    "    \n",
    "    # Run all pages concurrently\n",
    "    results = await asyncio.gather(*tasks)\n",
    "    \n",
    "    # Simple results structure\n",
    "    enhanced_fields = {}\n",
    "    for page, result in results:\n",
    "        enhanced_fields[page] = result\n",
    "        print(f\"Page {page} processed\")\n",
    "    \n",
    "    return enhanced_fields\n",
    "\n",
    "# Usage\n",
    "enhanced_pa_data = await process_pa_fields_async(abdulla_pa_fields, \"Input Data/Abdulla/PA.pdf\")\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "953a9eec",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{2: '[\\n  {\\n    \"name\": \"CB1\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Start of treatment\",\\n    \"question\": \"Is this request for the start of a new treatment for the patient?\",\\n    \"context\": \"Initial checkbox in treatment timeline section indicating whether patient is beginning new therapy.\"\\n  },\\n  {\\n    \"name\": \"T2\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Start date: (MM)\",\\n    \"question\": \"What is the two-digit month for the treatment start date?\",\\n    \"context\": \"Month component for the planned medication initiation date in treatment scheduling section.\"\\n  },\\n  {\\n    \"name\": \"T3\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Start date: (DD)\",\\n    \"question\": \"What is the two-digit day for the treatment start date?\",\\n    \"context\": \"Day component for the planned medication initiation date in treatment scheduling section.\"\\n  },\\n  {\\n    \"name\": \"T4\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Start date: (YYYY)\",\\n    \"question\": \"What is the four-digit year for the treatment start date?\",\\n    \"context\": \"Year component for the planned medication initiation date in treatment scheduling section.\"\\n  },\\n  {\\n    \"name\": \"CB5\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Continuation of therapy\",\\n    \"question\": \"Is this request for the continuation of an existing therapy for the patient?\",\\n    \"context\": \"Checkbox indicating if the request is for ongoing treatment, as opposed to new initiation.\"\\n  },\\n  {\\n    \"name\": \"T6\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Date of last treatment: (MM)\",\\n    \"question\": \"What is the two-digit month of the patient\\'s last treatment?\",\\n    \"context\": \"Month component for the last treatment date, required for continuation of therapy requests.\"\\n  },\\n  {\\n    \"name\": \"T7\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Date of last treatment: (DD)\",\\n    \"question\": \"What is the two-digit day of the patient\\'s last treatment?\",\\n    \"context\": \"Day component for the last treatment date, required for continuation of therapy requests.\"\\n  },\\n  {\\n    \"name\": \"T8\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Date of last treatment: (YYYY)\",\\n    \"question\": \"What is the four-digit year of the patient\\'s last treatment?\",\\n    \"context\": \"Year component for the last treatment date, required for continuation of therapy requests.\"\\n  },\\n  {\\n    \"name\": \"T9\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Precertification Requested By:\",\\n    \"question\": \"Who is submitting this precertification request?\",\\n    \"context\": \"Identifies the individual or entity responsible for submitting the prior authorization request.\"\\n  },\\n  {\\n    \"name\": \"T10\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Phone:\",\\n    \"question\": \"What is the phone number of the person requesting precertification?\",\\n    \"context\": \"Contact phone number for follow-up regarding the submitted precertification request.\"\\n  },\\n  {\\n    \"name\": \"T11\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Fax:\",\\n    \"question\": \"What is the fax number of the person requesting precertification?\",\\n    \"context\": \"Contact fax number for sending or receiving precertification-related documents.\"\\n  },\\n  {\\n    \"name\": \"T12\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Patient First Name\",\\n    \"question\": \"What is the patient\\'s first name?\",\\n    \"context\": \"Primary demographic information for patient identification in the Patient Information section.\"\\n  },\\n  {\\n    \"name\": \"T13\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Patient Last Name\",\\n    \"question\": \"What is the patient\\'s last name?\",\\n    \"context\": \"Primary demographic information for patient identification in the Patient Information section.\"\\n  },\\n  {\\n    \"name\": \"T14\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Patient DOB (MM/DD/YYYY)\",\\n    \"question\": \"What is the patient\\'s date of birth (MM/DD/YYYY)?\",\\n    \"context\": \"Patient\\'s full date of birth, essential for age verification and accurate record matching.\"\\n  },\\n  {\\n    \"name\": \"T15\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Address:\",\\n    \"question\": \"What is the patient\\'s home address?\",\\n    \"context\": \"Patient\\'s residential street address for contact and demographic records.\"\\n  },\\n  {\\n    \"name\": \"T16\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"City:\",\\n    \"question\": \"What is the patient\\'s home city?\",\\n    \"context\": \"Patient\\'s city of residence, part of the complete home address.\"\\n  },\\n  {\\n    \"name\": \"T17\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"State:\",\\n    \"question\": \"What is the patient\\'s home state?\",\\n    \"context\": \"Patient\\'s state of residence, part of the complete home address.\"\\n  },\\n  {\\n    \"name\": \"T18\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"ZIP:\",\\n    \"question\": \"What is the patient\\'s home ZIP code?\",\\n    \"context\": \"Patient\\'s ZIP code, completing the demographic home address details.\"\\n  },\\n  {\\n    \"name\": \"T19\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Patient Phone\",\\n    \"question\": \"What is the patient\\'s home phone number?\",\\n    \"context\": \"Patient\\'s primary home contact number for communication purposes.\"\\n  },\\n  {\\n    \"name\": \"T20\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Work Phone:\",\\n    \"question\": \"What is the patient\\'s work phone number?\",\\n    \"context\": \"Patient\\'s alternative work contact number, if applicable, for communication.\"\\n  },\\n  {\\n    \"name\": \"T21\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Cell Phone:\",\\n    \"question\": \"What is the patient\\'s cell phone number?\",\\n    \"context\": \"Patient\\'s mobile contact number, important for direct communication.\"\\n  },\\n  {\\n    \"name\": \"T22\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"E-mail:\",\\n    \"question\": \"What is the patient\\'s email address?\",\\n    \"context\": \"Patient\\'s email address for electronic communication and record-keeping.\"\\n  },\\n  {\\n    \"name\": \"T24\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"lbs\",\\n    \"question\": \"What is the patient\\'s current weight in pounds (lbs)?\",\\n    \"context\": \"Patient\\'s current weight in pounds, used for calculating medication dosage and clinical assessment.\"\\n  },\\n  {\\n    \"name\": \"T25\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"kgs\",\\n    \"question\": \"What is the patient\\'s current weight in kilograms (kgs)?\",\\n    \"context\": \"Patient\\'s current weight in kilograms, alternative unit for medication dosage calculation.\"\\n  },\\n  {\\n    \"name\": \"T26\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"inches\",\\n    \"question\": \"What is the patient\\'s current height in inches?\",\\n    \"context\": \"Patient\\'s current height in inches, used for Body Surface Area (BSA) calculations.\"\\n  },\\n  {\\n    \"name\": \"T27\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"cms\",\\n    \"question\": \"What is the patient\\'s current height in centimeters (cms)?\",\\n    \"context\": \"Patient\\'s current height in centimeters, alternative unit for BSA calculations.\"\\n  },\\n  {\\n    \"name\": \"T23\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Allergies:\",\\n    \"question\": \"What are the patient\\'s known allergies?\",\\n    \"context\": \"Lists all patient allergies, critical for medication safety and preventing adverse reactions.\"\\n  },\\n  {\\n    \"name\": \"T28\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Member ID #:\",\\n    \"question\": \"What is the patient\\'s insurance member ID number?\",\\n    \"context\": \"Patient\\'s unique insurance identification number for eligibility and benefits verification.\"\\n  },\\n  {\\n    \"name\": \"T29\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Group #:\",\\n    \"question\": \"What is the patient\\'s insurance group number?\",\\n    \"context\": \"Patient\\'s insurance group number, identifying their specific plan or employer group.\"\\n  },\\n  {\\n    \"name\": \"T30\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Insured:\",\\n    \"question\": \"Who is the primary insured party on the patient\\'s policy?\",\\n    \"context\": \"Name of the primary policyholder if different from the patient, for insurance verification.\"\\n  },\\n  {\\n    \"name\": \"CB31\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Does the patient have other insurance coverage?\",\\n    \"context\": \"Indicates if the patient has additional primary or secondary health insurance coverage.\"\\n  },\\n  {\\n    \"name\": \"CB32\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"No\",\\n    \"question\": \"Does the patient not have other insurance coverage?\",\\n    \"context\": \"Indicates if the patient solely relies on this insurance, without other coverage.\"\\n  },\\n  {\\n    \"name\": \"T33\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"If yes, provide ID#:\",\\n    \"question\": \"If yes, what is the ID number for the patient\\'s other coverage?\",\\n    \"context\": \"Requires the ID number for any additional insurance coverage the patient may have.\"\\n  },\\n  {\\n    \"name\": \"T34\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Carrier Name:\",\\n    \"question\": \"What is the carrier name of the patient\\'s other insurance?\",\\n    \"context\": \"Name of the insurance company providing the patient\\'s other health coverage.\"\\n  },\\n  {\\n    \"name\": \"T35\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Insured:\",\\n    \"question\": \"Who is the primary insured party on the patient\\'s other policy?\",\\n    \"context\": \"Name of the primary policyholder for the patient\\'s other insurance coverage.\"\\n  },\\n  {\\n    \"name\": \"T42\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"First Name:\",\\n    \"question\": \"What is the prescriber\\'s first name?\",\\n    \"context\": \"Prescriber\\'s first name for identification and verification in the Prescriber Information section.\"\\n  },\\n  {\\n    \"name\": \"T43\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Last Name:\",\\n    \"question\": \"What is the prescriber\\'s last name?\",\\n    \"context\": \"Prescriber\\'s last name for identification and verification in the Prescriber Information section.\"\\n  },\\n  {\\n    \"name\": \"CB44\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"M.D.\",\\n    \"question\": \"Is the prescriber an M.D. (Medical Doctor)?\",\\n    \"context\": \"Prescriber\\'s professional credential (Medical Doctor) for licensing and qualification verification.\"\\n  },\\n  {\\n    \"name\": \"CB45\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"D.O.\",\\n    \"question\": \"Is the prescriber a D.O. (Doctor of Osteopathic Medicine)?\",\\n    \"context\": \"Prescriber\\'s professional credential (Doctor of Osteopathic Medicine) for licensing verification.\"\\n  },\\n  {\\n    \"name\": \"CB46\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"N.P.\",\\n    \"question\": \"Is the prescriber an N.P. (Nurse Practitioner)?\",\\n    \"context\": \"Prescriber\\'s professional credential (Nurse Practitioner) for licensing and qualification verification.\"\\n  },\\n  {\\n    \"name\": \"CB47\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"P.A.\",\\n    \"question\": \"Is the prescriber a P.A. (Physician Assistant)?\",\\n    \"context\": \"Prescriber\\'s professional credential (Physician Assistant) for licensing and qualification verification.\"\\n  },\\n  {\\n    \"name\": \"T48\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Address:\",\\n    \"question\": \"What is the prescriber\\'s office address?\",\\n    \"context\": \"Prescriber\\'s primary office street address for contact and record-keeping.\"\\n  },\\n  {\\n    \"name\": \"T49\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"City:\",\\n    \"question\": \"What is the city of the prescriber\\'s office?\",\\n    \"context\": \"City of the prescriber\\'s office, part of the complete office address.\"\\n  },\\n  {\\n    \"name\": \"T50\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"State:\",\\n    \"question\": \"What is the state of the prescriber\\'s office?\",\\n    \"context\": \"State of the prescriber\\'s office, part of the complete office address.\"\\n  },\\n  {\\n    \"name\": \"T51\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"ZIP:\",\\n    \"question\": \"What is the ZIP code of the prescriber\\'s office?\",\\n    \"context\": \"ZIP code of the prescriber\\'s office, completing the office address details.\"\\n  },\\n  {\\n    \"name\": \"T52\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Phone:\",\\n    \"question\": \"What is the prescriber\\'s office phone number?\",\\n    \"context\": \"Prescriber\\'s primary office contact number for direct communication.\"\\n  },\\n  {\\n    \"name\": \"T53\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Fax:\",\\n    \"question\": \"What is the prescriber\\'s office fax number?\",\\n    \"context\": \"Prescriber\\'s office fax number for sending or receiving medical documentation.\"\\n  },\\n  {\\n    \"name\": \"T54\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"St Lic #:\",\\n    \"question\": \"What is the prescriber\\'s state license number?\",\\n    \"context\": \"Prescriber\\'s state medical license number, essential for verification of credentials.\"\\n  },\\n  {\\n    \"name\": \"T55\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"NPI #:\",\\n    \"question\": \"What is the prescriber\\'s NPI (National Provider Identifier) number?\",\\n    \"context\": \"Prescriber\\'s unique NPI for standardized identification in healthcare transactions.\"\\n  },\\n  {\\n    \"name\": \"T56\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"DEA #:\",\\n    \"question\": \"What is the prescriber\\'s DEA (Drug Enforcement Administration) number?\",\\n    \"context\": \"Prescriber\\'s DEA registration number, required for prescribing controlled substances.\"\\n  },\\n  {\\n    \"name\": \"T57\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"UPIN:\",\\n    \"question\": \"What is the prescriber\\'s UPIN (Unique Physician Identification Number)?\",\\n    \"context\": \"Prescriber\\'s UPIN, if applicable, for physician identification (legacy identifier).\"\\n  },\\n  {\\n    \"name\": \"T58.0\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Provider Email:\",\\n    \"question\": \"What is the prescriber\\'s email address?\",\\n    \"context\": \"Prescriber\\'s email address for electronic communication regarding patient care.\"\\n  },\\n  {\\n    \"name\": \"T58.1\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Office Contact Name:\",\\n    \"question\": \"What is the name of the primary contact person at the prescriber\\'s office?\",\\n    \"context\": \"Name of a key administrative contact at the prescriber\\'s office for PA inquiries.\"\\n  },\\n  {\\n    \"name\": \"T59\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Phone:\",\\n    \"question\": \"What is the phone number for the prescriber\\'s office contact?\",\\n    \"context\": \"Direct phone number for the specified office contact person, if different from main office.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin CB.1\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Self-administered\",\\n    \"question\": \"Is the medication self-administered by the patient?\",\\n    \"context\": \"Indicates if the patient takes the medication independently, affecting dispensing location.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin CB.2\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Physician’s Office\",\\n    \"question\": \"Will the medication be administered in the physician\\'s office?\",\\n    \"context\": \"Indicates the medication will be administered at the prescriber\\'s office, common for infused drugs.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin CB.3\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Home\",\\n    \"question\": \"Will the medication be administered at the patient\\'s home?\",\\n    \"context\": \"Indicates if the patient will receive the medication at home, common for home health services.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin CB.4\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Outpatient Infusion Center\",\\n    \"question\": \"Will the medication be administered at an outpatient infusion center?\",\\n    \"context\": \"Indicates administration at a dedicated outpatient infusion facility.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.5\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Name:\",\\n    \"question\": \"What is the name of the outpatient infusion center?\",\\n    \"context\": \"Name of the specific outpatient infusion center where medication will be administered.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin CB.7\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Home Infusion Center\",\\n    \"question\": \"Will the medication be administered by a home infusion center?\",\\n    \"context\": \"Indicates if a specialized home infusion service will administer the medication at home.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.6\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Phone:\",\\n    \"question\": \"What is the phone number of the home infusion center?\",\\n    \"context\": \"Phone number of the home infusion center for scheduling and coordination.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.8\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Agency Name:\",\\n    \"question\": \"What is the name of the home infusion agency?\",\\n    \"context\": \"Name of the home infusion agency providing services, if applicable.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin CB.10\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Administration code(s)\",\\n    \"question\": \"Are administration code(s) being provided for this request?\",\\n    \"context\": \"Checkbox to indicate if relevant CPT administration codes will be included for the service.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.9\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"CPT:\",\\n    \"question\": \"What are the CPT administration code(s) for this service?\",\\n    \"context\": \"Specific CPT codes for the medication\\'s administration, vital for billing and service description.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.11A\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Address:\",\\n    \"question\": \"What is the address for the dispensing provider/administration location?\",\\n    \"context\": \"Street address of the dispensing provider or administration facility.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.13\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"City:\",\\n    \"question\": \"What is the city for the dispensing provider/administration location?\",\\n    \"context\": \"City of the dispensing provider or administration facility.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.14\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"State:\",\\n    \"question\": \"What is the state for the dispensing provider/administration location?\",\\n    \"context\": \"State of the dispensing provider or administration facility.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.15\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"ZIP:\",\\n    \"question\": \"What is the ZIP code for the dispensing provider/administration location?\",\\n    \"context\": \"ZIP code of the dispensing provider or administration facility.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.16\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Phone:\",\\n    \"question\": \"What is the phone number for the dispensing provider/administration location?\",\\n    \"context\": \"Contact phone number for the dispensing provider or administration facility.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.17A\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Fax:\",\\n    \"question\": \"What is the fax number for the dispensing provider/administration location?\",\\n    \"context\": \"Fax number for the dispensing provider or administration facility for document transmission.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.18\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"TIN:\",\\n    \"question\": \"What is the Tax Identification Number (TIN) for the dispensing provider/administration location?\",\\n    \"context\": \"TIN of the dispensing provider or administration facility, used for tax and billing purposes.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.19\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"PIN:\",\\n    \"question\": \"What is the Provider Identification Number (PIN) for the dispensing provider/administration location?\",\\n    \"context\": \"PIN of the dispensing provider or administration facility for unique identification.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.20\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"NPI:\",\\n    \"question\": \"What is the NPI (National Provider Identifier) for the dispensing provider/administration location?\",\\n    \"context\": \"NPI of the dispensing provider or administration facility for standardized identification.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin CB.21\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Outpatient Dialysis Center\",\\n    \"question\": \"Will the medication be dispensed/administered at an outpatient dialysis center?\",\\n    \"context\": \"Checkbox indicating if the medication will be provided by an outpatient dialysis center.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin CB.22\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Physician’s Office\",\\n    \"question\": \"Will the medication be dispensed/administered at a physician\\'s office?\",\\n    \"context\": \"Checkbox indicating if the medication will be provided by a physician\\'s office.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin CB.23.0.0\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Retail Pharmacy\",\\n    \"question\": \"Will the medication be dispensed by a retail pharmacy?\",\\n    \"context\": \"Checkbox indicating if the medication will be obtained from a retail pharmacy.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin CB.24.0.0\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Specialty Pharmacy\",\\n    \"question\": \"Will the medication be dispensed by a specialty pharmacy?\",\\n    \"context\": \"Checkbox indicating if the medication will be obtained from a specialty pharmacy.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin CB.25\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Mail Order\",\\n    \"question\": \"Will the medication be dispensed by mail order?\",\\n    \"context\": \"Checkbox indicating if the medication will be delivered via mail order pharmacy services.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin CB.26\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Other:\",\\n    \"question\": \"Will the medication be dispensed/administered by another type of facility not listed?\",\\n    \"context\": \"Option to specify an alternative dispensing or administration location not pre-listed.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.27\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Other:\",\\n    \"question\": \"Please specify the \\'Other\\' dispensing/administration location.\",\\n    \"context\": \"Text field to describe the specific \\'other\\' dispensing/administration location if the checkbox is selected.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.28\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Name:\",\\n    \"question\": \"What is the name of the dispensing provider/pharmacy?\",\\n    \"context\": \"Name of the entity responsible for dispensing the medication.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.29a\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Address:\",\\n    \"question\": \"What is the address of the dispensing provider/pharmacy?\",\\n    \"context\": \"Street address of the dispensing provider or pharmacy.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.30a\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"City:\",\\n    \"question\": \"What is the city of the dispensing provider/pharmacy?\",\\n    \"context\": \"City of the dispensing provider or pharmacy.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.31\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"State:\",\\n    \"question\": \"What is the state of the dispensing provider/pharmacy?\",\\n    \"context\": \"State of the dispensing provider or pharmacy.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.32\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"ZIP:\",\\n    \"question\": \"What is the ZIP code of the dispensing provider/pharmacy?\",\\n    \"context\": \"ZIP code of the dispensing provider or pharmacy.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.33\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Phone:\",\\n    \"question\": \"What is the phone number for the dispensing provider/pharmacy?\",\\n    \"context\": \"Contact phone number for the dispensing provider or pharmacy.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.34\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Fax:\",\\n    \"question\": \"What is the fax number for the dispensing provider/pharmacy?\",\\n    \"context\": \"Fax number for the dispensing provider or pharmacy for document transmission.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.35\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"TIN:\",\\n    \"question\": \"What is the Tax Identification Number (TIN) for the dispensing provider/pharmacy?\",\\n    \"context\": \"TIN of the dispensing provider or pharmacy for tax and billing purposes.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.36\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"PIN:\",\\n    \"question\": \"What is the Provider Identification Number (PIN) for the dispensing provider/pharmacy?\",\\n    \"context\": \"PIN of the dispensing provider or pharmacy for unique identification.\"\\n  },\\n  {\\n    \"name\": \"Provider Admin T.37\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"NPI:\",\\n    \"question\": \"What is the NPI (National Provider Identifier) for the dispensing provider/pharmacy?\",\\n    \"context\": \"NPI of the dispensing provider or pharmacy for standardized identification.\"\\n  },\\n  {\\n    \"name\": \"CB60\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Riabni (rituximab-arrx)\",\\n    \"question\": \"Is the requested product Riabni (rituximab-arrx)?\",\\n    \"context\": \"Selection for Riabni, a non-preferred rituximab biosimilar, in the Product Information section.\"\\n  },\\n  {\\n    \"name\": \"CB61\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Rituxan (rituximab)\",\\n    \"question\": \"Is the requested product Rituxan (rituximab)?\",\\n    \"context\": \"Selection for Rituxan, a non-preferred rituximab product, in the Product Information section.\"\\n  },\\n  {\\n    \"name\": \"CB62\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Ruxience (rituximab-pvvr)\",\\n    \"question\": \"Is the requested product Ruxience (rituximab-pvvr)?\",\\n    \"context\": \"Selection for Ruxience, a preferred rituximab biosimilar, in the Product Information section.\"\\n  },\\n  {\\n    \"name\": \"CB63\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Truxima (rituximab-abbs)\",\\n    \"question\": \"Is the requested product Truxima (rituximab-abbs)?\",\\n    \"context\": \"Selection for Truxima, a preferred rituximab biosimilar, in the Product Information section.\"\\n  },\\n  {\\n    \"name\": \"T64\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Dose:\",\\n    \"question\": \"What is the prescribed dose of the requested medication?\",\\n    \"context\": \"Prescribed dosage of the medication, essential for clinical review and safety.\"\\n  },\\n  {\\n    \"name\": \"T65\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Directions for Use:\",\\n    \"question\": \"What are the directions for use of the requested medication?\",\\n    \"context\": \"Instructions for medication administration, including frequency and route, for clinical assessment.\"\\n  },\\n  {\\n    \"name\": \"T66\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"HCPCS Code:\",\\n    \"question\": \"What is the HCPCS code for the requested medication or service?\",\\n    \"context\": \"HCPCS code identifying the specific drug or service for billing and coverage determination.\"\\n  },\\n  {\\n    \"name\": \"T67\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Primary ICD Code:\",\\n    \"question\": \"What is the primary ICD code for the patient\\'s diagnosis?\",\\n    \"context\": \"Primary International Classification of Diseases (ICD) code describing the patient\\'s main diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB68\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Other ICD Code:\",\\n    \"question\": \"Are there other ICD codes applicable to the patient\\'s diagnosis?\",\\n    \"context\": \"Checkbox indicating if additional ICD codes will be provided for other relevant diagnoses.\"\\n  },\\n  {\\n    \"name\": \"T69\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Other ICD Code:\",\\n    \"question\": \"What are the other applicable ICD codes?\",\\n    \"context\": \"Lists additional ICD codes for co-morbidities or secondary diagnoses, if applicable.\"\\n  },\\n  {\\n    \"name\": \"CB70\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Has the patient received prior therapy with the requested product within the last 365 days?\",\\n    \"context\": \"Indicates if the patient has recent experience with the specific medication being requested.\"\\n  },\\n  {\\n    \"name\": \"CB71\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"No\",\\n    \"question\": \"Has the patient not received prior therapy with the requested product within the last 365 days?\",\\n    \"context\": \"Indicates if the patient has no recent history of therapy with the requested medication.\"\\n  },\\n  {\\n    \"name\": \"CB72\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"No\",\\n    \"question\": \"Has the patient NOT had a trial and failure of any rituximab biosimilars listed?\",\\n    \"context\": \"Indicates if the patient has not failed preferred rituximab biosimilars, influencing product selection.\"\\n  },\\n  {\\n    \"name\": \"CB73\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Ruxience (rituximab-pvvr)\",\\n    \"question\": \"Has the patient had a trial and failure of Ruxience (rituximab-pvvr)?\",\\n    \"context\": \"Indicates if the patient has failed a trial of the preferred rituximab biosimilar Ruxience.\"\\n  },\\n  {\\n    \"name\": \"CB74\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Truxima (rituximab-abbs)\",\\n    \"question\": \"Has the patient had a trial and failure of Truxima (rituximab-abbs)?\",\\n    \"context\": \"Indicates if the patient has failed a trial of the preferred rituximab biosimilar Truxima.\"\\n  },\\n  {\\n    \"name\": \"T75\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"When was the member’s trial and failure of the preferred drug?\",\\n    \"question\": \"When did the patient\\'s trial and failure of the preferred drug occur?\",\\n    \"context\": \"Date of documented trial failure of preferred biosimilars, supporting the current request.\"\\n  },\\n  {\\n    \"name\": \"T76\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Please describe the nature of the failure of the preferred drug\",\\n    \"question\": \"What was the nature of the patient\\'s failure with the preferred drug?\",\\n    \"context\": \"Detailed explanation of why the preferred medication failed, for medical necessity review.\"\\n  },\\n  {\\n    \"name\": \"CB77\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"No\",\\n    \"question\": \"Has the patient NOT had an adverse reaction to any rituximab biosimilars listed?\",\\n    \"context\": \"Indicates if the patient has not experienced adverse reactions to preferred rituximab biosimilars.\"\\n  },\\n  {\\n    \"name\": \"CB78\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Ruxience (rituximab-pvvr)\",\\n    \"question\": \"Has the patient had an adverse reaction to Ruxience (rituximab-pvvr)?\" ,\\n    \"context\": \"Indicates if the patient experienced an adverse reaction to the preferred biosimilar Ruxience.\"\\n  },\\n  {\\n    \"name\": \"CB79\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Truxima (rituximab-abbs)\",\\n    \"question\": \"Has the patient had an adverse reaction to Truxima (rituximab-abbs)?\",\\n    \"context\": \"Indicates if the patient experienced an adverse reaction to the preferred biosimilar Truxima.\"\\n  },\\n  {\\n    \"name\": \"T80\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"When was the member’s adverse reaction to the preferred drug?\",\\n    \"question\": \"When did the patient\\'s adverse reaction to the preferred drug occur?\",\\n    \"context\": \"Date of documented adverse reaction to preferred biosimilars, supporting current request.\"\\n  },\\n  {\\n    \"name\": \"T81\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Please describe the nature of the adverse reaction to the preferred drug\",\\n    \"question\": \"What was the nature of the patient\\'s adverse reaction to the preferred drug?\",\\n    \"context\": \"Detailed explanation of the adverse reaction to the preferred medication, for medical necessity.\"\\n  },\\n  {\\n    \"name\": \"T84\",\\n    \"type\": \"text\",\\n    \"page\": 2,\\n    \"field_label\": \"Please explain if there are any contraindications or other medical reason(s) that the patient cannot use any of the following preferred biosimilar products when indicated for the patient’s diagnosis?\",\\n    \"question\": \"Please explain any contraindications or medical reasons preventing the patient from using preferred rituximab biosimilars.\",\\n    \"context\": \"Requires a clinical justification for not using preferred biosimilar rituximab options, if applicable.\"\\n  },\\n  {\\n    \"name\": \"CB82\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Ruxience (rituximab-pvvr)\",\\n    \"question\": \"Is Ruxience (rituximab-pvvr) contraindicated or medically unsuitable for the patient\\'s diagnosis?\",\\n    \"context\": \"Indicates a contraindication or medical reason preventing the use of Ruxience for the patient.\"\\n  },\\n  {\\n    \"name\": \"CB83\",\\n    \"type\": \"checkbox\",\\n    \"page\": 2,\\n    \"field_label\": \"Truxima (rituximab-abbs)\",\\n    \"question\": \"Is Truxima (rituximab-abbs) contraindicated or medically unsuitable for the patient\\'s diagnosis?\",\\n    \"context\": \"Indicates a contraindication or medical reason preventing the use of Truxima for the patient.\"\\n  }\\n]',\n",
       " 3: '[\\n  {\\n    \"name\": \"T12\",\\n    \"type\": \"text\",\\n    \"page\": 3,\\n    \"field_label\": \"Patient First Name\",\\n    \"question\": \"What is the patient\\'s first name?\",\\n    \"context\": \"Patient\\'s given name, essential for identification in the clinical information section.\"\\n  },\\n  {\\n    \"name\": \"T13\",\\n    \"type\": \"text\",\\n    \"page\": 3,\\n    \"field_label\": \"Patient Last Name\",\\n    \"question\": \"What is the patient\\'s last name?\",\\n    \"context\": \"Patient\\'s surname, crucial for accurate identification within the clinical data.\"\\n  },\\n  {\\n    \"name\": \"T19\",\\n    \"type\": \"text\",\\n    \"page\": 3,\\n    \"field_label\": \"Patient Phone\",\\n    \"question\": \"What is the patient\\'s phone number?\",\\n    \"context\": \"Patient\\'s contact phone number for communication regarding clinical information or requests.\"\\n  },\\n  {\\n    \"name\": \"T14\",\\n    \"type\": \"text\",\\n    \"page\": 3,\\n    \"field_label\": \"Patient DOB (MM/DD/YYYY)\",\\n    \"question\": \"What is the patient\\'s date of birth?\",\\n    \"context\": \"Patient\\'s date of birth in MM/DD/YYYY format for age verification and patient matching.\"\\n  },\\n  {\\n    \"name\": \"CB86\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Inflectra (infliximab-dyyb)\",\\n    \"question\": \"Has the patient had a trial and failure of Inflectra (infliximab-dyyb)?\",\\n    \"context\": \"Indicates if Inflectra, a preferred biosimilar, was tried and failed as prior therapy.\"\\n  },\\n  {\\n    \"name\": \"CB87\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Renflexis (infliximab-abda)\",\\n    \"question\": \"Has the patient had a trial and failure of Renflexis (infliximab-abda)?\",\\n    \"context\": \"Indicates if Renflexis, a preferred biosimilar, was tried and failed as prior therapy.\"\\n  },\\n  {\\n    \"name\": \"CB88\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Simponi Aria (golimumab)\",\\n    \"question\": \"Has the patient had a trial and failure of Simponi Aria (golimumab)?\",\\n    \"context\": \"Indicates if Simponi Aria, a preferred biologic, was tried and failed as prior therapy.\"\\n  },\\n  {\\n    \"name\": \"T89\",\\n    \"type\": \"text\",\\n    \"page\": 3,\\n    \"field_label\": \"When was the member’s trial and failure of the preferred drug?\",\\n    \"question\": \"When did the patient experience trial and failure of the preferred drug?\",\\n    \"context\": \"Date of trial and failure for the previously selected preferred biosimilar or biologic.\"\\n  },\\n  {\\n    \"name\": \"T90\",\\n    \"type\": \"text\",\\n    \"page\": 3,\\n    \"field_label\": \"Please describe the nature of the failure of the preferred drug\",\\n    \"question\": \"Please describe how the preferred drug trial failed.\",\\n    \"context\": \"Detailed explanation of clinical reasons for failure of prior preferred therapy.\"\\n  },\\n  {\\n    \"name\": \"CB85\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"No\",\\n    \"question\": \"Has the patient NOT had a trial and failure of Inflectra, Renflexis, or Simponi Aria?\",\\n    \"context\": \"Indicates no prior trial and failure of listed preferred therapies for patient. Dependent on parent question.\"\\n  },\\n  {\\n    \"name\": \"CB92\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Inflectra (infliximab-dyyb)\",\\n    \"question\": \"Has the patient had an adverse reaction to Inflectra (infliximab-dyyb)?\",\\n    \"context\": \"Indicates if Inflectra, a preferred biosimilar, caused an adverse reaction for patient.\"\\n  },\\n  {\\n    \"name\": \"CB93\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Renflexis (infliximab-abda)\",\\n    \"question\": \"Has the patient had an adverse reaction to Renflexis (infliximab-abda)?\",\\n    \"context\": \"Indicates if Renflexis, a preferred biosimilar, caused an adverse reaction for patient.\"\\n  },\\n  {\\n    \"name\": \"CB94\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Simponi Aria (golimumab)\",\\n    \"question\": \"Has the patient had an adverse reaction to Simponi Aria (golimumab)?\",\\n    \"context\": \"Indicates if Simponi Aria, a preferred biologic, caused an adverse reaction for patient.\"\\n  },\\n  {\\n    \"name\": \"T95\",\\n    \"type\": \"text\",\\n    \"page\": 3,\\n    \"field_label\": \"When was the member’s adverse reaction to the preferred drug?\",\\n    \"question\": \"When did the patient experience an adverse reaction to the preferred drug?\",\\n    \"context\": \"Date of adverse reaction to the previously selected preferred biosimilar or biologic.\"\\n  },\\n  {\\n    \"name\": \"T96a\",\\n    \"type\": \"text\",\\n    \"page\": 3,\\n    \"field_label\": \"Please describe the nature of the adverse reaction to the preferred drug\",\\n    \"question\": \"Please describe the adverse reaction to the preferred drug.\",\\n    \"context\": \"Detailed explanation of the adverse event encountered with prior preferred therapy.\"\\n  },\\n  {\\n    \"name\": \"CB91\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"No\",\\n    \"question\": \"Has the patient NOT had an adverse reaction to Inflectra, Renflexis, or Simponi Aria?\",\\n    \"context\": \"Indicates no prior adverse reaction to listed preferred therapies for patient. Dependent on parent question.\"\\n  },\\n  {\\n    \"name\": \"CB98a\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Enbrel (etanercept)\",\\n    \"question\": \"Has the patient had a trial and failure of Enbrel (etanercept)?\",\\n    \"context\": \"Indicates if Enbrel, a preferred MA plan therapy, was tried and failed as prior therapy.\"\\n  },\\n  {\\n    \"name\": \"CB99a\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Humira (adalimumab)\",\\n    \"question\": \"Has the patient had a trial and failure of Humira (adalimumab)?\",\\n    \"context\": \"Indicates if Humira, a preferred MA plan therapy, was tried and failed as prior therapy.\"\\n  },\\n  {\\n    \"name\": \"CB100a\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Idacio (adalimumab-aacf)\",\\n    \"question\": \"Has the patient had a trial and failure of Idacio (adalimumab-aacf)?\",\\n    \"context\": \"Indicates if Idacio, a preferred MA plan therapy, was tried and failed as prior therapy.\"\\n  },\\n  {\\n    \"name\": \"CB101a\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Rinvoq (upadacitinib)\",\\n    \"question\": \"Has the patient had a trial and failure of Rinvoq (upadacitinib)?\",\\n    \"context\": \"Indicates if Rinvoq, a preferred MA plan therapy, was tried and failed as prior therapy.\"\\n  },\\n  {\\n    \"name\": \"CB102a\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Tyenne SC (tocilizumab-aazg)\",\\n    \"question\": \"Has the patient had a trial and failure of Tyenne SC (tocilizumab-aazg)?\",\\n    \"context\": \"Indicates if Tyenne SC, a preferred MA plan therapy, was tried and failed as prior therapy.\"\\n  },\\n  {\\n    \"name\": \"CB103a\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Xeljanz/Xeljanz XR (tofacitinib)\",\\n    \"question\": \"Has the patient had a trial and failure of Xeljanz/Xeljanz XR (tofacitinib)?\",\\n    \"context\": \"Indicates if Xeljanz/Xeljanz XR, a preferred MA plan therapy, was tried and failed as prior therapy.\"\\n  },\\n  {\\n    \"name\": \"T104\",\\n    \"type\": \"text\",\\n    \"page\": 3,\\n    \"field_label\": \"When was the member’s trial and failure of the preferred drug?\",\\n    \"question\": \"When did the patient experience trial and failure of the preferred drug?\",\\n    \"context\": \"Date of trial and failure for the previously selected preferred MA plan drug.\"\\n  },\\n  {\\n    \"name\": \"T105\",\\n    \"type\": \"text\",\\n    \"page\": 3,\\n    \"field_label\": \"Please describe the nature of the failure of the preferred drug\",\\n    \"question\": \"Please describe how the preferred drug trial failed.\",\\n    \"context\": \"Detailed explanation of clinical reasons for failure of prior preferred MA plan therapy.\"\\n  },\\n  {\\n    \"name\": \"CB97\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"No\",\\n    \"question\": \"Has the patient NOT had a trial and failure of any listed preferred MA plan drug?\",\\n    \"context\": \"Indicates no prior trial and failure of listed preferred MA plan therapies for patient. Dependent on parent question.\"\\n  },\\n  {\\n    \"name\": \"CB107z\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Enbrel (etanercept)\",\\n    \"question\": \"Has the patient had an adverse reaction to Enbrel (etanercept)?\",\\n    \"context\": \"Indicates if Enbrel, a preferred MA plan therapy, caused an adverse reaction for patient.\"\\n  },\\n  {\\n    \"name\": \"CB108z\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Humira (adalimumab)\",\\n    \"question\": \"Has the patient had an adverse reaction to Humira (adalimumab)?\",\\n    \"context\": \"Indicates if Humira, a preferred MA plan therapy, caused an adverse reaction for patient.\"\\n  },\\n  {\\n    \"name\": \"CB109z\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Idacio (adalimumab-aacf)\",\\n    \"question\": \"Has the patient had an adverse reaction to Idacio (adalimumab-aacf)?\",\\n    \"context\": \"Indicates if Idacio, a preferred MA plan therapy, caused an adverse reaction for patient.\"\\n  },\\n  {\\n    \"name\": \"CB110z\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Rinvoq (upadacitinib)\",\\n    \"question\": \"Has the patient had an adverse reaction to Rinvoq (upadacitinib)?\",\\n    \"context\": \"Indicates if Rinvoq, a preferred MA plan therapy, caused an adverse reaction for patient.\"\\n  },\\n  {\\n    \"name\": \"CB111z\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Tyenne SC (tocilizumab-aazg)\",\\n    \"question\": \"Has the patient had an adverse reaction to Tyenne SC (tocilizumab-aazg)?\",\\n    \"context\": \"Indicates if Tyenne SC, a preferred MA plan therapy, caused an adverse reaction for patient.\"\\n  },\\n  {\\n    \"name\": \"CB112z\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Xeljanz/Xeljanz XR (tofacitinib)\",\\n    \"question\": \"Has the patient had an adverse reaction to Xeljanz/Xeljanz XR (tofacitinib)?\",\\n    \"context\": \"Indicates if Xeljanz/Xeljanz XR, a preferred MA plan therapy, caused an adverse reaction for patient.\"\\n  },\\n  {\\n    \"name\": \"T113\",\\n    \"type\": \"text\",\\n    \"page\": 3,\\n    \"field_label\": \"When was the member’s adverse reaction to the preferred drug?\",\\n    \"question\": \"When did the patient experience an adverse reaction to the preferred drug?\",\\n    \"context\": \"Date of adverse reaction to the previously selected preferred MA plan drug.\"\\n  },\\n  {\\n    \"name\": \"T114\",\\n    \"type\": \"text\",\\n    \"page\": 3,\\n    \"field_label\": \"Please describe the nature of the adverse reaction to the preferred drug\",\\n    \"question\": \"Please describe the adverse reaction to the preferred drug.\",\\n    \"context\": \"Detailed explanation of the adverse event encountered with prior preferred MA plan therapy.\"\\n  },\\n  {\\n    \"name\": \"CB106z\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"No\",\\n    \"question\": \"Has the patient NOT had an adverse reaction to any listed preferred MA plan drug?\",\\n    \"context\": \"Indicates no prior adverse reaction to listed preferred MA plan therapies for patient. Dependent on parent question.\"\\n  },\\n  {\\n    \"name\": \"T118\",\\n    \"type\": \"text\",\\n    \"page\": 3,\\n    \"field_label\": \"Please explain if there are any contraindications or other medical reason(s) that the patient cannot use any of the following preferred products when indicated for the patient’s diagnosis?\",\\n    \"question\": \"Please explain contraindications or other medical reasons preventing the patient from using the preferred biosimilars (Inflectra, Renflexis, Simponi Aria) for the diagnosis.\",\\n    \"context\": \"Explanation for not using preferred infliximab biosimilars/biologic due to contraindications or other medical reasons.\"\\n  },\\n  {\\n    \"name\": \"CB115z\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Inflectra (infliximab-dyyb)\",\\n    \"question\": \"Is Inflectra (infliximab-dyyb) contraindicated for this patient\\'s diagnosis?\",\\n    \"context\": \"Indicates if Inflectra is contraindicated for the patient\\'s specific diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB116z\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Renflexis (infliximab-abda)\",\\n    \"question\": \"Is Renflexis (infliximab-abda) contraindicated for this patient\\'s diagnosis?\",\\n    \"context\": \"Indicates if Renflexis is contraindicated for the patient\\'s specific diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB117z\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Simponi Aria (golimumab)\",\\n    \"question\": \"Is Simponi Aria (golimumab) contraindicated for this patient\\'s diagnosis?\",\\n    \"context\": \"Indicates if Simponi Aria is contraindicated for the patient\\'s specific diagnosis.\"\\n  },\\n  {\\n    \"name\": \"T125\",\\n    \"type\": \"text\",\\n    \"page\": 3,\\n    \"field_label\": \"Please explain if there are contraindications or any other medical reason(s) that the patient cannot use any of the following preferred products when indicated for the patient’s diagnosis?\",\\n    \"question\": \"Please explain contraindications or other medical reasons preventing the patient from using the preferred MA plan drugs (Enbrel, Humira, Idacio, Rinvoq, Tyenne SC, Xeljanz/Xeljanz XR) for the diagnosis.\",\\n    \"context\": \"Explanation for not using preferred MA plan drugs due to contraindications or other medical reasons for patient\\'s diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB119z\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Enbrel (etanercept)\",\\n    \"question\": \"Is Enbrel (etanercept) contraindicated for this patient\\'s diagnosis?\",\\n    \"context\": \"Indicates if Enbrel is contraindicated for the patient\\'s specific diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB120z\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Humira (adalimumab)\",\\n    \"question\": \"Is Humira (adalimumab) contraindicated for this patient\\'s diagnosis?\",\\n    \"context\": \"Indicates if Humira is contraindicated for the patient\\'s specific diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB121z\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Idacio (adalimumab-aacf)\",\\n    \"question\": \"Is Idacio (adalimumab-aacf) contraindicated for this patient\\'s diagnosis?\",\\n    \"context\": \"Indicates if Idacio is contraindicated for the patient\\'s specific diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB122z\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Rinvoq (upadacitinib)\",\\n    \"question\": \"Is Rinvoq (upadacitinib) contraindicated for this patient\\'s diagnosis?\",\\n    \"context\": \"Indicates if Rinvoq is contraindicated for the patient\\'s specific diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB123z\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Tyenne SC (tocilizumab-aazg)\",\\n    \"question\": \"Is Tyenne SC (tocilizumab-aazg) contraindicated for this patient\\'s diagnosis?\",\\n    \"context\": \"Indicates if Tyenne SC is contraindicated for the patient\\'s specific diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB124z\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Xeljanz/Xeljanz XR (tofacitinib)\",\\n    \"question\": \"Is Xeljanz/Xeljanz XR (tofacitinib) contraindicated for this patient\\'s diagnosis?\",\\n    \"context\": \"Indicates if Xeljanz/Xeljanz XR is contraindicated for the patient\\'s specific diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB96.4.0\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Will Rituxan be used concomitantly with apremilast, tofacitinib, or other biologic DMARDs?\",\\n    \"context\": \"Indicates if Rituxan will be co-administered with other DMARDs, relevant for drug interaction assessment.\"\\n  },\\n  {\\n    \"name\": \"CB98\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"No\",\\n    \"question\": \"Will Rituxan NOT be used concomitantly with apremilast, tofacitinib, or other biologic DMARDs?\",\\n    \"context\": \"Indicates no co-administration of Rituxan with other DMARDs, relevant for drug interaction assessment.\"\\n  },\\n  {\\n    \"name\": \"CB99.0\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Does the patient have a documented diagnosis of Philadelphia chromosome-negative acute lymphoid leukemia (ALL)?\",\\n    \"context\": \"Confirms patient\\'s diagnosis of specific acute lymphoid leukemia subtype.\"\\n  },\\n  {\\n    \"name\": \"CB100.0\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"No\",\\n    \"question\": \"Does the patient NOT have a documented diagnosis of Philadelphia chromosome-negative acute lymphoid leukemia (ALL)?\",\\n    \"context\": \"Denies specific acute lymphoid leukemia diagnosis for the patient.\"\\n  },\\n  {\\n    \"name\": \"CB101.0\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Is Rituxan (rituximab) being used as induction/consolidation therapy for ALL?\",\\n    \"context\": \"Confirms Rituxan\\'s role as induction/consolidation therapy for acute lymphoid leukemia.\"\\n  },\\n  {\\n    \"name\": \"CB102.0\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"No\",\\n    \"question\": \"Is Rituxan (rituximab) NOT being used as induction/consolidation therapy for ALL?\",\\n    \"context\": \"Denies Rituxan\\'s role as induction/consolidation therapy for acute lymphoid leukemia.\"\\n  },\\n  {\\n    \"name\": \"CB103\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Does the patient have a documented diagnosis of refractory autoimmune hemolytic anemia?\",\\n    \"context\": \"Confirms patient\\'s diagnosis of autoimmune hemolytic anemia refractory to other treatments.\"\\n  },\\n  {\\n    \"name\": \"CB104\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"No\",\\n    \"question\": \"Does the patient NOT have a documented diagnosis of refractory autoimmune hemolytic anemia?\",\\n    \"context\": \"Denies refractory autoimmune hemolytic anemia diagnosis for the patient.\"\\n  },\\n  {\\n    \"name\": \"CB104a\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Wegener granulomatosis\",\\n    \"question\": \"Does the patient have Wegener granulomatosis?\",\\n    \"context\": \"Identifies Wegener granulomatosis as the specific ANCA-associated vasculitis diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB104b\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Churg-Strauss syndrome\",\\n    \"question\": \"Does the patient have Churg-Strauss syndrome?\",\\n    \"context\": \"Identifies Churg-Strauss syndrome as the specific ANCA-associated vasculitis diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB104c\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"microscopic polyangiitis\",\\n    \"question\": \"Does the patient have microscopic polyangiitis?\",\\n    \"context\": \"Identifies microscopic polyangiitis as the specific ANCA-associated vasculitis diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB104d\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"pauci-immune glomerulonephritis\",\\n    \"question\": \"Does the patient have pauci-immune glomerulonephritis?\",\\n    \"context\": \"Identifies pauci-immune glomerulonephritis as the specific ANCA-associated vasculitis diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB105\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Will Rituxan (rituximab) be given in conjunction with glucocorticoids?\",\\n    \"context\": \"Indicates if Rituxan will be co-administered with glucocorticoids for ANCA-associated vasculitides treatment.\"\\n  },\\n  {\\n    \"name\": \"CB106\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"No\",\\n    \"question\": \"Will Rituxan (rituximab) NOT be given in conjunction with glucocorticoids?\",\\n    \"context\": \"Indicates no co-administration of Rituxan with glucocorticoids for ANCA-associated vasculitides treatment.\"\\n  },\\n  {\\n    \"name\": \"CB106a\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Does the patient have a documented diagnosis of corticosteroid-refractory autoimmune blistering disease?\",\\n    \"context\": \"Confirms patient\\'s diagnosis of autoimmune blistering disease refractory to corticosteroids.\"\\n  },\\n  {\\n    \"name\": \"CB107\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"pemphigus vulgaris\",\\n    \"question\": \"Does the patient have pemphigus vulgaris?\",\\n    \"context\": \"Identifies pemphigus vulgaris as the specific autoimmune blistering disease diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB108\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"pemphigus folliaceus\",\\n    \"question\": \"Does the patient have pemphigus folliaceus?\",\\n    \"context\": \"Identifies pemphigus folliaceus as the specific autoimmune blistering disease diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB109\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"bullous pemphigoid\",\\n    \"question\": \"Does the patient have bullous pemphigoid?\",\\n    \"context\": \"Identifies bullous pemphigoid as the specific autoimmune blistering disease diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB110\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"cicatricial pemphigoid\",\\n    \"question\": \"Does the patient have cicatricial pemphigoid?\",\\n    \"context\": \"Identifies cicatricial pemphigoid as the specific autoimmune blistering disease diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB111\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"epidermolysis bullosa acquisita\",\\n    \"question\": \"Does the patient have epidermolysis bullosa acquisita?\",\\n    \"context\": \"Identifies epidermolysis bullosa acquisita as the specific autoimmune blistering disease diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB112\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"paraneoplastic pemphigus\",\\n    \"question\": \"Does the patient have paraneoplastic pemphigus?\",\\n    \"context\": \"Identifies paraneoplastic pemphigus as the specific autoimmune blistering disease diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB113\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"None of the above\",\\n    \"question\": \"Is the patient\\'s autoimmune blistering disease NOT among the listed options?\",\\n    \"context\": \"Indicates if the patient\\'s specific autoimmune blistering disease diagnosis is not provided in the list.\"\\n  },\\n  {\\n    \"name\": \"CB106b\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"No\",\\n    \"question\": \"Does the patient NOT have a documented diagnosis of corticosteroid-refractory autoimmune blistering disease?\",\\n    \"context\": \"Denies corticosteroid-refractory autoimmune blistering disease diagnosis for the patient.\"\\n  },\\n  {\\n    \"name\": \"CB114\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"AIDS-related B-cell lymphoma\",\\n    \"question\": \"Does the patient have AIDS-related B-cell lymphoma?\",\\n    \"context\": \"Identifies AIDS-related B-cell lymphoma as the specific B-cell lymphoma diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB115\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Burkitt lymphoma\",\\n    \"question\": \"Does the patient have Burkitt lymphoma?\",\\n    \"context\": \"Identifies Burkitt lymphoma as the specific B-cell lymphoma diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB116\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Diffuse large B-cell lymphoma\",\\n    \"question\": \"Does the patient have Diffuse large B-cell lymphoma?\",\\n    \"context\": \"Identifies diffuse large B-cell lymphoma as the specific B-cell lymphoma diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB117\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Follicular lymphoma\",\\n    \"question\": \"Does the patient have Follicular lymphoma?\",\\n    \"context\": \"Identifies follicular lymphoma as the specific B-cell lymphoma diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB118\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Gastric MALT lymphoma\",\\n    \"question\": \"Does the patient have Gastric MALT lymphoma?\",\\n    \"context\": \"Identifies gastric MALT lymphoma as the specific B-cell lymphoma diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB119\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"High-grade B-Cell lymphoma\",\\n    \"question\": \"Does the patient have High-grade B-Cell lymphoma?\",\\n    \"context\": \"Identifies high-grade B-Cell lymphoma as the specific B-cell lymphoma diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB120\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Mantle cell lymphoma\",\\n    \"question\": \"Does the patient have Mantle cell lymphoma?\",\\n    \"context\": \"Identifies mantle cell lymphoma as the specific B-cell lymphoma diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB121\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Nodal marginal zone lymphoma\",\\n    \"question\": \"Does the patient have Nodal marginal zone lymphoma?\",\\n    \"context\": \"Identifies nodal marginal zone lymphoma as the specific B-cell lymphoma diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB122\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Nongastric MALT lymphoma\",\\n    \"question\": \"Does the patient have Nongastric MALT lymphoma?\",\\n    \"context\": \"Identifies nongastric MALT lymphoma as the specific B-cell lymphoma diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB123\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Primary cutaneous B-cell lymphomas\",\\n    \"question\": \"Does the patient have Primary cutaneous B-cell lymphomas?\",\\n    \"context\": \"Identifies primary cutaneous B-cell lymphomas as the specific B-cell lymphoma diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB124\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Splenic marginal zone lymphoma\",\\n    \"question\": \"Does the patient have Splenic marginal zone lymphoma?\",\\n    \"context\": \"Identifies splenic marginal zone lymphoma as the specific B-cell lymphoma diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB125\",\\n    \"type\": \"checkbox\",\\n    \"page\": 3,\\n    \"field_label\": \"Other:\",\\n    \"question\": \"Does the patient have an \\'Other\\' type of B-cell lymphoma not listed?\",\\n    \"context\": \"Indicates if the patient\\'s B-cell lymphoma diagnosis falls outside the provided categories.\"\\n  },\\n  {\\n    \"name\": \"T126\",\\n    \"type\": \"text\",\\n    \"page\": 3,\\n    \"field_label\": \"Other:\",\\n    \"question\": \"Please specify the other type of B-cell lymphoma.\",\\n    \"context\": \"Text field to specify a B-cell lymphoma diagnosis not found in the predefined list.\"\\n  }\\n]',\n",
       " 4: '[\\n  {\\n    \"name\": \"T12\",\\n    \"type\": \"text\",\\n    \"page\": 4,\\n    \"field_label\": \"Patient First Name\",\\n    \"question\": \"What is the patient\\'s first name?\",\\n    \"context\": \"Patient\\'s demographic information, required for identification and linking to medical records.\"\\n  },\\n  {\\n    \"name\": \"T13\",\\n    \"type\": \"text\",\\n    \"page\": 4,\\n    \"field_label\": \"Patient Last Name\",\\n    \"question\": \"What is the patient\\'s last name?\",\\n    \"context\": \"Patient\\'s demographic information, required for identification and linking to medical records.\"\\n  },\\n  {\\n    \"name\": \"T19\",\\n    \"type\": \"text\",\\n    \"page\": 4,\\n    \"field_label\": \"Patient Phone\",\\n    \"question\": \"What is the patient\\'s phone number?\",\\n    \"context\": \"Patient\\'s contact information for communication regarding the prior authorization request.\"\\n  },\\n  {\\n    \"name\": \"T14\",\\n    \"type\": \"text\",\\n    \"page\": 4,\\n    \"field_label\": \"Patient DOB (MM/DD/YYYY)\",\\n    \"question\": \"What is the patient\\'s date of birth?\",\\n    \"context\": \"Patient\\'s demographic information, essential for accurate identification and age verification.\"\\n  },\\n  {\\n    \"name\": \"CB127\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Does the patient have a documented diagnosis of multicentric Castleman\\'s disease?\",\\n    \"context\": \"Primary question for Castleman\\'s disease, confirming patient\\'s diagnosis for treatment eligibility.\"\\n  },\\n  {\\n    \"name\": \"CB128\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"No\",\\n    \"question\": \"Does the patient NOT have a documented diagnosis of multicentric Castleman\\'s disease?\",\\n    \"context\": \"Primary question for Castleman\\'s disease, confirming patient\\'s diagnosis for treatment eligibility.\"\\n  },\\n  {\\n    \"name\": \"CB129\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"leptomeningeal metastases from lymphoma\",\\n    \"question\": \"Does the patient\\'s central nervous system lymphoma involve leptomeningeal metastases?\",\\n    \"context\": \"Sub-question for Central Nervous System Lymphomas, specifying disease manifestation for treatment protocol.\"\\n  },\\n  {\\n    \"name\": \"CB130\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"primary CNS lymphoma\",\\n    \"question\": \"Does the patient have primary CNS lymphoma?\",\\n    \"context\": \"Sub-question for Central Nervous System Lymphomas, identifying the specific type of lymphoma.\"\\n  },\\n  {\\n    \"name\": \"CB131\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"none of the above\",\\n    \"question\": \"Are none of the above central nervous system lymphoma types applicable to the patient?\",\\n    \"context\": \"Sub-question for Central Nervous System Lymphomas, indicating if patient\\'s condition falls outside specified types.\"\\n  },\\n  {\\n    \"name\": \"CB132\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"chronic lymphocytic leukemia (CLL)\",\\n    \"question\": \"Does the patient have chronic lymphocytic leukemia (CLL)?\",\\n    \"context\": \"Sub-question for Chronic or Small Lymphocytic Leukemia, specifying the leukemia type for treatment.\"\\n  },\\n  {\\n    \"name\": \"CB133\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"small lymphocytic leukemia\",\\n    \"question\": \"Does the patient have small lymphocytic leukemia?\",\\n    \"context\": \"Sub-question for Chronic or Small Lymphocytic Leukemia, specifying the leukemia type for treatment.\"\\n  },\\n  {\\n    \"name\": \"CB134\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"none of the above\",\\n    \"question\": \"Are none of the above chronic or small lymphocytic leukemia types applicable to the patient?\",\\n    \"context\": \"Sub-question for Chronic or Small Lymphocytic Leukemia, indicating if patient\\'s condition falls outside specified types.\"\\n  },\\n  {\\n    \"name\": \"CB135\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Does the patient have a documented diagnosis of cryoglobulinemia?\",\\n    \"context\": \"Primary question for Cryoglobulinemia, confirming the patient\\'s diagnosis for treatment eligibility.\"\\n  },\\n  {\\n    \"name\": \"CB136\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"No\",\\n    \"question\": \"Does the patient NOT have a documented diagnosis of cryoglobulinemia?\",\\n    \"context\": \"Primary question for Cryoglobulinemia, confirming the patient\\'s diagnosis for treatment eligibility.\"\\n  },\\n  {\\n    \"name\": \"CB139\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Is there clinical documentation that corticosteroids and other immunosuppressive agents were ineffective for cryoglobulinemia?\",\\n    \"context\": \"Follow-up question for Cryoglobulinemia, assessing prior treatment failure with conventional therapies.\"\\n  },\\n  {\\n    \"name\": \"CB140\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"No\",\\n    \"question\": \"Is there NO clinical documentation that corticosteroids and other immunosuppressive agents were ineffective for cryoglobulinemia?\",\\n    \"context\": \"Follow-up question for Cryoglobulinemia, assessing prior treatment failure with conventional therapies.\"\\n  },\\n  {\\n    \"name\": \"CB144\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Is there documentation that Rituxan (rituximab) is being used as a last-resort treatment for chronic graft versus host disease (GVHD)?\",\\n    \"context\": \"Primary question for Chronic Graft Versus Host Disease, verifying Rituxan\\'s role as a salvage therapy.\"\\n  },\\n  {\\n    \"name\": \"CB145\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"No\",\\n    \"question\": \"Is there NO documentation that Rituxan (rituximab) is being used as a last-resort treatment for chronic graft versus host disease (GVHD)?\",\\n    \"context\": \"Primary question for Chronic Graft Versus Host Disease, verifying Rituxan\\'s role as a salvage therapy.\"\\n  },\\n  {\\n    \"name\": \"CB141\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"relapsed hairy cell leukemia\",\\n    \"question\": \"Does the patient have relapsed hairy cell leukemia?\",\\n    \"context\": \"Sub-question for Hairy Cell Leukemia, specifying if the disease has recurred after initial treatment.\"\\n  },\\n  {\\n    \"name\": \"CB142\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"refractory hairy cell leukemia\",\\n    \"question\": \"Does the patient have refractory hairy cell leukemia?\",\\n    \"context\": \"Sub-question for Hairy Cell Leukemia, indicating if the disease is unresponsive to prior treatments.\"\\n  },\\n  {\\n    \"name\": \"CB143\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"none of the above\",\\n    \"question\": \"Are none of the above hairy cell leukemia types applicable to the patient?\",\\n    \"context\": \"Sub-question for Hairy Cell Leukemia, indicating if patient\\'s condition falls outside specified types.\"\\n  },\\n  {\\n    \"name\": \"CB137\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Is there documentation that Rituxan (rituximab) is being used for treatment or prevention of antibody-mediated rejection in heart or other solid organ transplant recipients?\",\\n    \"context\": \"Primary question for Heart and Solid Organ Transplant, confirming Rituxan\\'s use for rejection management.\"\\n  },\\n  {\\n    \"name\": \"CB146\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"heart transplant recipient\",\\n    \"question\": \"Is the patient a heart transplant recipient?\",\\n    \"context\": \"Sub-question for Heart and Solid Organ Transplant, specifying the type of organ transplant received by the patient.\"\\n  },\\n  {\\n    \"name\": \"CB147\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"other solid organ transplant recipient\",\\n    \"question\": \"Is the patient an other solid organ transplant recipient?\",\\n    \"context\": \"Sub-question for Heart and Solid Organ Transplant, specifying the type of organ transplant received by the patient.\"\\n  },\\n  {\\n    \"name\": \"CB138\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"No\",\\n    \"question\": \"Is there NO documentation that Rituxan (rituximab) is being used for treatment or prevention of antibody-mediated rejection in heart or other solid organ transplant recipients?\",\\n    \"context\": \"Primary question for Heart and Solid Organ Transplant, confirming Rituxan\\'s use for rejection management.\"\\n  },\\n  {\\n    \"name\": \"CB148\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Bavencio (avelumab)\",\\n    \"question\": \"Did Bavencio (avelumab) cause the immune checkpoint-inhibitor related encephalitis?\",\\n    \"context\": \"Sub-question for Immune Checkpoint-Inhibitor Related Encephalitis, identifying the causative agent for diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB149\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Imfinzi (durvalumab)\",\\n    \"question\": \"Did Imfinzi (durvalumab) cause the immune checkpoint-inhibitor related encephalitis?\",\\n    \"context\": \"Sub-question for Immune Checkpoint-Inhibitor Related Encephalitis, identifying the causative agent for diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB150\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Keytruda (pembrolizumab)\",\\n    \"question\": \"Did Keytruda (pembrolizumab) cause the immune checkpoint-inhibitor related encephalitis?\",\\n    \"context\": \"Sub-question for Immune Checkpoint-Inhibitor Related Encephalitis, identifying the causative agent for diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB151\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Opdivo (nivolumab)\",\\n    \"question\": \"Did Opdivo (nivolumab) cause the immune checkpoint-inhibitor related encephalitis?\",\\n    \"context\": \"Sub-question for Immune Checkpoint-Inhibitor Related Encephalitis, identifying the causative agent for diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB152\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Tecentriq (atezolizumab)\",\\n    \"question\": \"Did Tecentriq (atezolizumab) cause the immune checkpoint-inhibitor related encephalitis?\",\\n    \"context\": \"Sub-question for Immune Checkpoint-Inhibitor Related Encephalitis, identifying the causative agent for diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB153\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Yervoy (ipilimumab)\",\\n    \"question\": \"Did Yervoy (ipilimumab) cause the immune checkpoint-inhibitor related encephalitis?\",\\n    \"context\": \"Sub-question for Immune Checkpoint-Inhibitor Related Encephalitis, identifying the causative agent for diagnosis.\"\\n  },\\n  {\\n    \"name\": \"CB154\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Other:\",\\n    \"question\": \"Was an \\'Other\\' immune checkpoint-inhibitor the cause of the encephalitis?\",\\n    \"context\": \"Sub-question for Immune Checkpoint-Inhibitor Related Encephalitis, allowing specification of other causative agents.\"\\n  },\\n  {\\n    \"name\": \"T155\",\\n    \"type\": \"text\",\\n    \"page\": 4,\\n    \"field_label\": \"Other:\",\\n    \"question\": \"Please specify the \\'Other\\' immune checkpoint-inhibitor that caused the encephalitis.\",\\n    \"context\": \"Text field to detail other specific immune checkpoint inhibitors not listed for encephalitis causation.\"\\n  },\\n  {\\n    \"name\": \"CB156\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Does the patient have a documented diagnosis of refractory immune or idiopathic thrombocytopenic purpura (ITP)?\",\\n    \"context\": \"Primary question for Immune or Idiopathic Thrombocytopenic Purpura, confirming diagnosis for treatment.\"\\n  },\\n  {\\n    \"name\": \"CB158\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"refractory immune thrombocytopenic purpura\",\\n    \"question\": \"Does the patient have refractory immune thrombocytopenic purpura?\",\\n    \"context\": \"Sub-question for Immune or Idiopathic Thrombocytopenic Purpura, specifying if the ITP is unresponsive to prior treatment.\"\\n  },\\n  {\\n    \"name\": \"CB159\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"idiopathic thrombocytopenic purpura (ITP)\",\\n    \"question\": \"Does the patient have idiopathic thrombocytopenic purpura (ITP)?\",\\n    \"context\": \"Sub-question for Immune or Idiopathic Thrombocytopenic Purpura, specifying the type of purpura.\"\\n  },\\n  {\\n    \"name\": \"CB157\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"No\",\\n    \"question\": \"Does the patient NOT have a documented diagnosis of refractory immune or idiopathic thrombocytopenic purpura (ITP)?\",\\n    \"context\": \"Primary question for Immune or Idiopathic Thrombocytopenic Purpura, confirming diagnosis for treatment.\"\\n  },\\n  {\\n    \"name\": \"CB160\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Is Rituxan (rituximab) being used as rejection prophylaxis in sensitized kidney transplant recipients with donor specific antibodies?\",\\n    \"context\": \"Primary question for Kidney Transplant Rejection Prophylaxis, confirming Rituxan\\'s use in high-risk patients.\"\\n  },\\n  {\\n    \"name\": \"CB161\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"No\",\\n    \"question\": \"Is Rituxan (rituximab) NOT being used as rejection prophylaxis in sensitized kidney transplant recipients with donor specific antibodies?\",\\n    \"context\": \"Primary question for Kidney Transplant Rejection Prophylaxis, confirming Rituxan\\'s use in high-risk patients.\"\\n  },\\n  {\\n    \"name\": \"CB162\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Does the patient have a documented diagnosis of lymphocyte-predominant Hodgkin\\'s lymphoma?\",\\n    \"context\": \"Primary question for Lymphocyte-Predominant Hodgkin\\'s Lymphoma, confirming diagnosis for treatment eligibility.\"\\n  },\\n  {\\n    \"name\": \"CB163\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"No\",\\n    \"question\": \"Does the patient NOT have a documented diagnosis of lymphocyte-predominant Hodgkin\\'s lymphoma?\",\\n    \"context\": \"Primary question for Lymphocyte-Predominant Hodgkin\\'s Lymphoma, confirming diagnosis for treatment eligibility.\"\\n  },\\n  {\\n    \"name\": \"CB164\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Relapsing-remitting MS (RRMS)\",\\n    \"question\": \"Has the patient been diagnosed with Relapsing-remitting MS (RRMS)?\",\\n    \"context\": \"Sub-question for Multiple Sclerosis, specifying the patient\\'s diagnosed MS type for treatment context.\"\\n  },\\n  {\\n    \"name\": \"CB165\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Secondary-progressive MS (SPMS)\",\\n    \"question\": \"Has the patient been diagnosed with Secondary-progressive MS (SPMS)?\",\\n    \"context\": \"Sub-question for Multiple Sclerosis, specifying the patient\\'s diagnosed MS type for treatment context.\"\\n  },\\n  {\\n    \"name\": \"CB166\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Primary-progressive MS (PPMS)\",\\n    \"question\": \"Has the patient been diagnosed with Primary-progressive MS (PPMS)?\",\\n    \"context\": \"Sub-question for Multiple Sclerosis, specifying the patient\\'s diagnosed MS type for treatment context.\"\\n  },\\n  {\\n    \"name\": \"CB167\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Progressive-relapsing MS (PRMS)\",\\n    \"question\": \"Has the patient been diagnosed with Progressive-relapsing MS (PRMS)?\",\\n    \"context\": \"Sub-question for Multiple Sclerosis, specifying the patient\\'s diagnosed MS type for treatment context.\"\\n  },\\n  {\\n    \"name\": \"CB168\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Has the patient discontinued other medications used for treating MS (not including Ampyra)?\",\\n    \"context\": \"Follow-up question for Multiple Sclerosis, indicating prior treatment history and potential reasons for change.\"\\n  },\\n  {\\n    \"name\": \"CB169\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"No\",\\n    \"question\": \"Has the patient NOT discontinued other medications used for treating MS (not including Ampyra)?\",\\n    \"context\": \"Follow-up question for Multiple Sclerosis, indicating prior treatment history and potential reasons for change.\"\\n  },\\n  {\\n    \"name\": \"CB170\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Does the patient have a documented diagnosis of muscle-specific tyrosine kinase myasthenia gravis (MuSK-MG)?\",\\n    \"context\": \"Primary question for Myasthenia Gravis (MuSK-MG), confirming diagnosis for treatment eligibility.\"\\n  },\\n  {\\n    \"name\": \"CB172\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Has the patient had an unsatisfactory response to initial immunotherapy for MuSK-MG?\",\\n    \"context\": \"Follow-up question for Myasthenia Gravis (MuSK-MG), assessing failure of first-line treatments.\"\\n  },\\n  {\\n    \"name\": \"CB173\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"No\",\\n    \"question\": \"Has the patient NOT had an unsatisfactory response to initial immunotherapy for MuSK-MG?\",\\n    \"context\": \"Follow-up question for Myasthenia Gravis (MuSK-MG), assessing failure of first-line treatments.\"\\n  },\\n  {\\n    \"name\": \"CB171\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"No\",\\n    \"question\": \"Does the patient NOT have a documented diagnosis of muscle-specific tyrosine kinase myasthenia gravis (MuSK-MG)?\",\\n    \"context\": \"Primary question for Myasthenia Gravis (MuSK-MG), confirming diagnosis for treatment eligibility.\"\\n  },\\n  {\\n    \"name\": \"CB174\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Does the patient have a documented diagnosis of neuromyelitis optica (Devic\\'s disease)?\",\\n    \"context\": \"Primary question for Neuromyelitis Optica (Devic\\'s disease), confirming diagnosis for treatment eligibility.\"\\n  },\\n  {\\n    \"name\": \"CB175\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"No\",\\n    \"question\": \"Does the patient NOT have a documented diagnosis of neuromyelitis optica (Devic\\'s disease)?\",\\n    \"context\": \"Primary question for Neuromyelitis Optica (Devic\\'s disease), confirming diagnosis for treatment eligibility.\"\\n  },\\n  {\\n    \"name\": \"CB176\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Was the treatment with at least one immunotherapy ineffective for neuromyelitis optica?\",\\n    \"context\": \"Follow-up question for Neuromyelitis Optica, assessing prior treatment failure with immunotherapy.\"\\n  },\\n  {\\n    \"name\": \"CB177\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"No\",\\n    \"question\": \"Was the treatment with at least one immunotherapy NOT ineffective for neuromyelitis optica?\",\\n    \"context\": \"Follow-up question for Neuromyelitis Optica, assessing prior treatment failure with immunotherapy.\"\\n  },\\n  {\\n    \"name\": \"CB178\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Does the patient have a documented diagnosis of opsoclonus-myoclonus-ataxia (OMA) associated with neuroblastoma?\",\\n    \"context\": \"Primary question for Opsoclonus-Myoclonus-Ataxia, confirming diagnosis and association for treatment eligibility.\"\\n  },\\n  {\\n    \"name\": \"CB179\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"No\",\\n    \"question\": \"Does the patient NOT have a documented diagnosis of opsoclonus-myoclonus-ataxia (OMA) associated with neuroblastoma?\",\\n    \"context\": \"Primary question for Opsoclonus-Myoclonus-Ataxia, confirming diagnosis and association for treatment eligibility.\"\\n  },\\n  {\\n    \"name\": \"CB180\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Is the patient refractory to steroids, chemotherapy, and intravenous immunoglobulins for OMA?\",\\n    \"context\": \"Follow-up question for Opsoclonus-Myoclonus-Ataxia, assessing failure of multiple prior treatment lines.\"\\n  },\\n  {\\n    \"name\": \"T189\",\\n    \"type\": \"text\",\\n    \"page\": 4,\\n    \"field_label\": \"Medication:\",\\n    \"question\": \"What is the name of the first medication tried for OMA?\",\\n    \"context\": \"Details of prior medications used for Opsoclonus-Myoclonus-Ataxia, essential for demonstrating refractoriness.\"\\n  },\\n  {\\n    \"name\": \"T190\",\\n    \"type\": \"text\",\\n    \"page\": 4,\\n    \"field_label\": \"Date: (MM)\",\\n    \"question\": \"What is the month the first medication was started for OMA?\",\\n    \"context\": \"Month of administration for the first prior medication used for OMA, indicating treatment timeline.\"\\n  },\\n  {\\n    \"name\": \"T191\",\\n    \"type\": \"text\",\\n    \"page\": 4,\\n    \"field_label\": \"Date: (DD)\",\\n    \"question\": \"What is the day the first medication was started for OMA?\",\\n    \"context\": \"Day of administration for the first prior medication used for OMA, indicating treatment timeline.\"\\n  },\\n  {\\n    \"name\": \"T192\",\\n    \"type\": \"text\",\\n    \"page\": 4,\\n    \"field_label\": \"Date: (YYYY)\",\\n    \"question\": \"What is the year the first medication was started for OMA?\",\\n    \"context\": \"Year of administration for the first prior medication used for OMA, indicating treatment timeline.\"\\n  },\\n  {\\n    \"name\": \"T193\",\\n    \"type\": \"text\",\\n    \"page\": 4,\\n    \"field_label\": \"Date: (MM)\",\\n    \"question\": \"What is the month the first medication was ended for OMA?\",\\n    \"context\": \"Month of cessation for the first prior medication used for OMA, indicating treatment timeline.\"\\n  },\\n  {\\n    \"name\": \"T194\",\\n    \"type\": \"text\",\\n    \"page\": 4,\\n    \"field_label\": \"Date: (DD)\",\\n    \"question\": \"What is the day the first medication was ended for OMA?\",\\n    \"context\": \"Day of cessation for the first prior medication used for OMA, indicating treatment timeline.\"\\n  },\\n  {\\n    \"name\": \"T195\",\\n    \"type\": \"text\",\\n    \"page\": 4,\\n    \"field_label\": \"Date: (YYYY)\",\\n    \"question\": \"What is the year the first medication was ended for OMA?\",\\n    \"context\": \"Year of cessation for the first prior medication used for OMA, indicating treatment timeline.\"\\n  },\\n  {\\n    \"name\": \"T196\",\\n    \"type\": \"text\",\\n    \"page\": 4,\\n    \"field_label\": \"Medication:\",\\n    \"question\": \"What is the name of the second medication tried for OMA?\",\\n    \"context\": \"Details of prior medications used for Opsoclonus-Myoclonus-Ataxia, essential for demonstrating refractoriness.\"\\n  },\\n  {\\n    \"name\": \"T197\",\\n    \"type\": \"text\",\\n    \"page\": 4,\\n    \"field_label\": \"Date: (MM)\",\\n    \"question\": \"What is the month the second medication was started for OMA?\",\\n    \"context\": \"Month of administration for the second prior medication used for OMA, indicating treatment timeline.\"\\n  },\\n  {\\n    \"name\": \"T198\",\\n    \"type\": \"text\",\\n    \"page\": 4,\\n    \"field_label\": \"Date: (DD)\",\\n    \"question\": \"What is the day the second medication was started for OMA?\",\\n    \"context\": \"Day of administration for the second prior medication used for OMA, indicating treatment timeline.\"\\n  },\\n  {\\n    \"name\": \"T199\",\\n    \"type\": \"text\",\\n    \"page\": 4,\\n    \"field_label\": \"Date: (YYYY)\",\\n    \"question\": \"What is the year the second medication was started for OMA?\",\\n    \"context\": \"Year of administration for the second prior medication used for OMA, indicating treatment timeline.\"\\n  },\\n  {\\n    \"name\": \"T200\",\\n    \"type\": \"text\",\\n    \"page\": 4,\\n    \"field_label\": \"Date: (MM)\",\\n    \"question\": \"What is the month the second medication was ended for OMA?\",\\n    \"context\": \"Month of cessation for the second prior medication used for OMA, indicating treatment timeline.\"\\n  },\\n  {\\n    \"name\": \"T201\",\\n    \"type\": \"text\",\\n    \"page\": 4,\\n    \"field_label\": \"Date: (DD)\",\\n    \"question\": \"What is the day the second medication was ended for OMA?\",\\n    \"context\": \"Day of cessation for the second prior medication used for OMA, indicating treatment timeline.\"\\n  },\\n  {\\n    \"name\": \"T202\",\\n    \"type\": \"text\",\\n    \"page\": 4,\\n    \"field_label\": \"Date: (YYYY)\",\\n    \"question\": \"What is the year the second medication was ended for OMA?\",\\n    \"context\": \"Year of cessation for the second prior medication used for OMA, indicating treatment timeline.\"\\n  },\\n  {\\n    \"name\": \"CB181\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"No\",\\n    \"question\": \"Is the patient NOT refractory to steroids, chemotherapy, and intravenous immunoglobulins for OMA?\",\\n    \"context\": \"Follow-up question for Opsoclonus-Myoclonus-Ataxia, assessing failure of multiple prior treatment lines.\"\\n  },\\n  {\\n    \"name\": \"CB203\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Is Rituxan (rituximab) being used as treatment of post-transplant lymphoproliferative disorder?\",\\n    \"context\": \"Primary question for Post-transplant Lymphoproliferative Disorder, confirming Rituxan\\'s use as treatment.\"\\n  },\\n  {\\n    \"name\": \"CB204\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"No\",\\n    \"question\": \"Is Rituxan (rituximab) NOT being used as treatment of post-transplant lymphoproliferative disorder?\",\\n    \"context\": \"Primary question for Post-transplant Lymphoproliferative Disorder, confirming Rituxan\\'s use as treatment.\"\\n  },\\n  {\\n    \"name\": \"CB205\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Is Rituxan (rituximab) being used as prophylaxis for Epstein-Barr virus (EBV) post-transplant lymphoproliferative disorder?\",\\n    \"context\": \"Follow-up question for Post-transplant Lymphoproliferative Disorder, confirming Rituxan\\'s use for EBV prophylaxis.\"\\n  },\\n  {\\n    \"name\": \"CB206\",\\n    \"type\": \"checkbox\",\\n    \"page\": 4,\\n    \"field_label\": \"No\",\\n    \"question\": \"Is Rituxan (rituximab) NOT being used as prophylaxis for Epstein-Barr virus (EBV) post-transplant lymphoproliferative disorder?\",\\n    \"context\": \"Follow-up question for Post-transplant Lymphoproliferative Disorder, confirming Rituxan\\'s use for EBV prophylaxis.\"\\n  }\\n]',\n",
       " 5: '[\\n  {\\n    \"name\": \"T12\",\\n    \"type\": \"text\",\\n    \"page\": 5,\\n    \"field_label\": \"Patient First Name\",\\n    \"question\": \"What is the patient\\'s first name?\",\\n    \"context\": \"Patient demographic information for identification purposes in the clinical information section.\"\\n  },\\n  {\\n    \"name\": \"T13\",\\n    \"type\": \"text\",\\n    \"page\": 5,\\n    \"field_label\": \"Patient Last Name\",\\n    \"question\": \"What is the patient\\'s last name?\",\\n    \"context\": \"Patient demographic information for identification purposes in the clinical information section.\"\\n  },\\n  {\\n    \"name\": \"T19\",\\n    \"type\": \"text\",\\n    \"page\": 5,\\n    \"field_label\": \"Patient Phone\",\\n    \"question\": \"What is the patient\\'s phone number?\",\\n    \"context\": \"Patient contact information for communication regarding the prior authorization request.\"\\n  },\\n  {\\n    \"name\": \"T14\",\\n    \"type\": \"text\",\\n    \"page\": 5,\\n    \"field_label\": \"Patient DOB (MM/DD/YYYY)\",\\n    \"question\": \"What is the patient\\'s date of birth?\",\\n    \"context\": \"Patient demographic information for identification and age verification purposes.\"\\n  },\\n  {\\n    \"name\": \"CB207\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"Mild\",\\n    \"question\": \"Is the patient\\'s rheumatoid arthritis considered mild?\",\\n    \"context\": \"Indicates the severity level of the patient\\'s rheumatoid arthritis for treatment eligibility.\"\\n  },\\n  {\\n    \"name\": \"CB208\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"Moderate\",\\n    \"question\": \"Is the patient\\'s rheumatoid arthritis considered moderate?\",\\n    \"context\": \"Indicates the severity level of the patient\\'s rheumatoid arthritis for treatment eligibility.\"\\n  },\\n  {\\n    \"name\": \"CB209\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"Severe\",\\n    \"question\": \"Is the patient\\'s rheumatoid arthritis considered severe?\",\\n    \"context\": \"Indicates the severity level of the patient\\'s rheumatoid arthritis for treatment eligibility.\"\\n  },\\n  {\\n    \"name\": \"CB210\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Is there evidence that the disease is active?\",\\n    \"context\": \"Confirms active disease state of rheumatoid arthritis, crucial for justifying treatment initiation.\"\\n  },\\n  {\\n    \"name\": \"CB211\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"No\",\\n    \"question\": \"Is there no evidence that the disease is active?\",\\n    \"context\": \"Indicates lack of active disease state of rheumatoid arthritis, may impact treatment approval.\"\\n  },\\n  {\\n    \"name\": \"CB212\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Will Rituxan (rituximab) be used in combination with methotrexate?\",\\n    \"context\": \"Determines if the requested drug will be part of a combination therapy for rheumatoid arthritis.\"\\n  },\\n  {\\n    \"name\": \"CB213\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"No\",\\n    \"question\": \"Will Rituxan (rituximab) not be used in combination with methotrexate?\",\\n    \"context\": \"Indicates Rituxan will be used as monotherapy or with other agents for rheumatoid arthritis.\"\\n  },\\n  {\\n    \"name\": \"CB214\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Has treatment with methotrexate been ineffective, not tolerated or contraindicated?\",\\n    \"context\": \"Assesses the patient\\'s response or tolerance to prior methotrexate therapy, a prerequisite for Rituxan.\"\\n  },\\n  {\\n    \"name\": \"CB216\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"ineffective\",\\n    \"question\": \"Was methotrexate treatment ineffective?\",\\n    \"context\": \"Specifies the reason for methotrexate failure, indicating the drug did not achieve desired clinical outcome.\"\\n  },\\n  {\\n    \"name\": \"CB217\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"not tolerated\",\\n    \"question\": \"Was methotrexate treatment not tolerated?\",\\n    \"context\": \"Specifies the reason for methotrexate failure, indicating patient experienced adverse effects.\"\\n  },\\n  {\\n    \"name\": \"CB218\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"contraindicated\",\\n    \"question\": \"Was methotrexate treatment contraindicated?\",\\n    \"context\": \"Specifies the reason for methotrexate failure, indicating medical reasons prevented its use.\"\\n  },\\n  {\\n    \"name\": \"CB215\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"No\",\\n    \"question\": \"Has treatment with methotrexate not been ineffective, not tolerated or contraindicated?\",\\n    \"context\": \"Indicates that methotrexate therapy was effective, tolerated, and not contraindicated.\"\\n  },\\n  {\\n    \"name\": \"CB223\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Was treatment with another conventional DMARD ineffective?\",\\n    \"context\": \"Assesses the patient\\'s response to other prior conventional DMARDs, a prerequisite for Rituxan.\"\\n  },\\n  {\\n    \"name\": \"CB225\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"azathioprine\",\\n    \"question\": \"Was azathioprine ineffective?\",\\n    \"context\": \"Indicates if azathioprine, a conventional DMARD, failed to control the patient\\'s condition.\"\\n  },\\n  {\\n    \"name\": \"CB226\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"cyclosporine\",\\n    \"question\": \"Was cyclosporine ineffective?\",\\n    \"context\": \"Indicates if cyclosporine, a conventional DMARD, failed to control the patient\\'s condition.\"\\n  },\\n  {\\n    \"name\": \"CB227\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"hydroxychloroquine\",\\n    \"question\": \"Was hydroxychloroquine ineffective?\",\\n    \"context\": \"Indicates if hydroxychloroquine, a conventional DMARD, failed to control the patient\\'s condition.\"\\n  },\\n  {\\n    \"name\": \"CB228\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"leflunomide\",\\n    \"question\": \"Was leflunomide ineffective?\",\\n    \"context\": \"Indicates if leflunomide, a conventional DMARD, failed to control the patient\\'s condition.\"\\n  },\\n  {\\n    \"name\": \"CB229\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"sulfasalazine\",\\n    \"question\": \"Was sulfasalazine ineffective?\",\\n    \"context\": \"Indicates if sulfasalazine, a conventional DMARD, failed to control the patient\\'s condition.\"\\n  },\\n  {\\n    \"name\": \"CB224\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"No\",\\n    \"question\": \"Was treatment with another conventional DMARD not ineffective?\",\\n    \"context\": \"Indicates that other conventional DMARD therapy was effective or tolerated.\"\\n  },\\n  {\\n    \"name\": \"CB281\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Does the patient have a documented diagnosis of Sjögren\\'s syndrome?\",\\n    \"context\": \"Confirms the primary diagnosis for which Rituxan is being requested, supporting medical necessity.\"\\n  },\\n  {\\n    \"name\": \"CB282\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"No\",\\n    \"question\": \"Does the patient not have a documented diagnosis of Sjögren\\'s syndrome?\",\\n    \"context\": \"Indicates the absence of Sjögren\\'s syndrome diagnosis, affecting treatment eligibility.\"\\n  },\\n  {\\n    \"name\": \"CB283\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Was treatment with corticosteroids and other immunosuppressive agents ineffective?\",\\n    \"context\": \"Evaluates prior therapy failure for Sjögren\\'s syndrome, justifying advanced treatment like Rituxan.\"\\n  },\\n  {\\n    \"name\": \"T285\",\\n    \"type\": \"text\",\\n    \"page\": 5,\\n    \"field_label\": \"Medication:\",\\n    \"question\": \"What is the name of the first corticosteroid or immunosuppressive agent used?\",\\n    \"context\": \"Details the specific prior medication used and its failure for Sjögren\\'s syndrome management.\"\\n  },\\n  {\\n    \"name\": \"T286\",\\n    \"type\": \"text\",\\n    \"page\": 5,\\n    \"field_label\": \"Date: (MM)\",\\n    \"question\": \"What is the month the first medication was started?\",\\n    \"context\": \"Month of administration for the first corticosteroid/immunosuppressive agent in Sjögren\\'s syndrome.\"\\n  },\\n  {\\n    \"name\": \"T287\",\\n    \"type\": \"text\",\\n    \"page\": 5,\\n    \"field_label\": \"Date: (DD)\",\\n    \"question\": \"What is the day the first medication was started?\",\\n    \"context\": \"Day of administration for the first corticosteroid/immunosuppressive agent in Sjögren\\'s syndrome.\"\\n  },\\n  {\\n    \"name\": \"T288\",\\n    \"type\": \"text\",\\n    \"page\": 5,\\n    \"field_label\": \"Date: (YYYY)\",\\n    \"question\": \"What is the year the first medication was started?\",\\n    \"context\": \"Year of administration for the first corticosteroid/immunosuppressive agent in Sjögren\\'s syndrome.\"\\n  },\\n  {\\n    \"name\": \"T289\",\\n    \"type\": \"text\",\\n    \"page\": 5,\\n    \"field_label\": \"Date: (MM)\",\\n    \"question\": \"What is the month the first medication was ended?\",\\n    \"context\": \"Month of cessation for the first corticosteroid/immunosuppressive agent in Sjögren\\'s syndrome.\"\\n  },\\n  {\\n    \"name\": \"T290\",\\n    \"type\": \"text\",\\n    \"page\": 5,\\n    \"field_label\": \"Date: (DD)\",\\n    \"question\": \"What is the day the first medication was ended?\",\\n    \"context\": \"Day of cessation for the first corticosteroid/immunosuppressive agent in Sjögren\\'s syndrome.\"\\n  },\\n  {\\n    \"name\": \"T291\",\\n    \"type\": \"text\",\\n    \"page\": 5,\\n    \"field_label\": \"Date: (YYYY)\",\\n    \"question\": \"What is the year the first medication was ended?\",\\n    \"context\": \"Year of cessation for the first corticosteroid/immunosuppressive agent in Sjögren\\'s syndrome.\"\\n  },\\n  {\\n    \"name\": \"T292\",\\n    \"type\": \"text\",\\n    \"page\": 5,\\n    \"field_label\": \"Medication:\",\\n    \"question\": \"What is the name of the second corticosteroid or immunosuppressive agent used?\",\\n    \"context\": \"Details the specific second prior medication used and its failure for Sjögren\\'s syndrome management.\"\\n  },\\n  {\\n    \"name\": \"T293\",\\n    \"type\": \"text\",\\n    \"page\": 5,\\n    \"field_label\": \"Date: (MM)\",\\n    \"question\": \"What is the month the second medication was started?\",\\n    \"context\": \"Month of administration for the second corticosteroid/immunosuppressive agent in Sjögren\\'s syndrome.\"\\n  },\\n  {\\n    \"name\": \"T294\",\\n    \"type\": \"text\",\\n    \"page\": 5,\\n    \"field_label\": \"Date: (DD)\",\\n    \"question\": \"What is the day the second medication was started?\",\\n    \"context\": \"Day of administration for the second corticosteroid/immunosuppressive agent in Sjögren\\'s syndrome.\"\\n  },\\n  {\\n    \"name\": \"T295\",\\n    \"type\": \"text\",\\n    \"page\": 5,\\n    \"field_label\": \"Date: (YYYY)\",\\n    \"question\": \"What is the year the second medication was started?\",\\n    \"context\": \"Year of administration for the second corticosteroid/immunosuppressive agent in Sjögren\\'s syndrome.\"\\n  },\\n  {\\n    \"name\": \"T296\",\\n    \"type\": \"text\",\\n    \"page\": 5,\\n    \"field_label\": \"Date: (MM)\",\\n    \"question\": \"What is the month the second medication was ended?\",\\n    \"context\": \"Month of cessation for the second corticosteroid/immunosuppressive agent in Sjögren\\'s syndrome.\"\\n  },\\n  {\\n    \"name\": \"T297\",\\n    \"type\": \"text\",\\n    \"page\": 5,\\n    \"field_label\": \"Date: (DD)\",\\n    \"question\": \"What is the day the second medication was ended?\",\\n    \"context\": \"Day of cessation for the second corticosteroid/immunosuppressive agent in Sjögren\\'s syndrome.\"\\n  },\\n  {\\n    \"name\": \"T298\",\\n    \"type\": \"text\",\\n    \"page\": 5,\\n    \"field_label\": \"Date: (YYYY)\",\\n    \"question\": \"What is the year the second medication was ended?\",\\n    \"context\": \"Year of cessation for the second corticosteroid/immunosuppressive agent in Sjögren\\'s syndrome.\"\\n  },\\n  {\\n    \"name\": \"CB284\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"No\",\\n    \"question\": \"Was treatment with corticosteroids and other immunosuppressive agents not ineffective?\",\\n    \"context\": \"Indicates prior corticosteroid/immunosuppressive therapy was effective or tolerated for Sjögren\\'s syndrome.\"\\n  },\\n  {\\n    \"name\": \"CB299\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Does the patient have a documented diagnosis of refractory thrombotic thrombocytopenic purpura (TTP)?\",\\n    \"context\": \"Confirms diagnosis of refractory TTP, indicating the severity and need for specific treatment.\"\\n  },\\n  {\\n    \"name\": \"CB300\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"No\",\\n    \"question\": \"Does the patient not have a documented diagnosis of refractory thrombotic thrombocytopenic purpura (TTP)?\",\\n    \"context\": \"Indicates absence of refractory TTP diagnosis, affecting treatment eligibility for Rituxan.\"\\n  },\\n  {\\n    \"name\": \"CB301\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Does the patient have a documented diagnosis of Waldenström macroglobulinemia?\",\\n    \"context\": \"Confirms diagnosis of Waldenström macroglobulinemia, essential for Rituxan coverage.\"\\n  },\\n  {\\n    \"name\": \"CB302\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"No\",\\n    \"question\": \"Does the patient not have a documented diagnosis of Waldenström macroglobulinemia?\",\\n    \"context\": \"Indicates absence of Waldenström macroglobulinemia diagnosis, affecting treatment eligibility.\"\\n  },\\n  {\\n    \"name\": \"CB303\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Is this continuation request a result of the patient receiving samples of Rituxan (rituximab)?\",\\n    \"context\": \"Determines if the current request is for continued therapy after receiving Rituxan samples.\"\\n  },\\n  {\\n    \"name\": \"CB304\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"No\",\\n    \"question\": \"Is this continuation request not a result of the patient receiving samples of Rituxan (rituximab)?\",\\n    \"context\": \"Indicates the continuation request is for other reasons, not post-sample use.\"\\n  },\\n  {\\n    \"name\": \"T305\",\\n    \"type\": \"text\",\\n    \"page\": 5,\\n    \"field_label\": \"Please indicate the length of time on Rituxan (rituximab):\",\\n    \"question\": \"What is the total length of time the patient has been on Rituxan (rituximab)?\",\\n    \"context\": \"Provides duration of Rituxan therapy, crucial for assessing ongoing efficacy and safety for continuation requests.\"\\n  },\\n  {\\n    \"name\": \"CB310\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"Mild\",\\n    \"question\": \"Was the severity of the disease at baseline (pretreatment with Rituxan (rituximab)) mild?\",\\n    \"context\": \"Assesses baseline rheumatoid arthritis severity to evaluate treatment effectiveness for continuation requests.\"\\n  },\\n  {\\n    \"name\": \"CB311\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"Moderate\",\\n    \"question\": \"Was the severity of the disease at baseline (pretreatment with Rituxan (rituximab)) moderate?\",\\n    \"context\": \"Assesses baseline rheumatoid arthritis severity to evaluate treatment effectiveness for continuation requests.\"\\n  },\\n  {\\n    \"name\": \"CB312\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"Severe\",\\n    \"question\": \"Was the severity of the disease at baseline (pretreatment with Rituxan (rituximab)) severe?\",\\n    \"context\": \"Assesses baseline rheumatoid arthritis severity to evaluate treatment effectiveness for continuation requests.\"\\n  },\\n  {\\n    \"name\": \"CB306\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Is there clinical documentation supporting disease stability?\",\\n    \"context\": \"Confirms clinical documentation showing stable disease for continued Rituxan therapy in rheumatoid arthritis.\"\\n  },\\n  {\\n    \"name\": \"CB307\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"No\",\\n    \"question\": \"Is there no clinical documentation supporting disease stability?\",\\n    \"context\": \"Indicates lack of documentation for disease stability, potentially impacting Rituxan continuation for RA.\"\\n  },\\n  {\\n    \"name\": \"CB308\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Is there clinical documentation supporting disease improvement?\",\\n    \"context\": \"Confirms clinical documentation showing disease improvement for continued Rituxan therapy in rheumatoid arthritis.\"\\n  },\\n  {\\n    \"name\": \"CB309\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"No\",\\n    \"question\": \"Is there no clinical documentation supporting disease improvement?\",\\n    \"context\": \"Indicates lack of documentation for disease improvement, potentially impacting Rituxan continuation for RA.\"\\n  },\\n  {\\n    \"name\": \"CB313\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Is there clinical documentation supporting disease stability?\",\\n    \"context\": \"Confirms clinical documentation showing stable disease for continued Rituxan therapy for other indications.\"\\n  },\\n  {\\n    \"name\": \"CB314\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"No\",\\n    \"question\": \"Is there no clinical documentation supporting disease stability?\",\\n    \"context\": \"Indicates lack of documentation for disease stability, potentially impacting Rituxan continuation for other indications.\"\\n  },\\n  {\\n    \"name\": \"CB315\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"Yes\",\\n    \"question\": \"Is there clinical documentation supporting disease improvement?\",\\n    \"context\": \"Confirms clinical documentation showing disease improvement for continued Rituxan therapy for other indications.\"\\n  },\\n  {\\n    \"name\": \"CB316\",\\n    \"type\": \"checkbox\",\\n    \"page\": 5,\\n    \"field_label\": \"No\",\\n    \"question\": \"Is there no clinical documentation supporting disease improvement?\",\\n    \"context\": \"Indicates lack of documentation for disease improvement, potentially impacting Rituxan continuation for other indications.\"\\n  },\\n  {\\n    \"name\": \"T317\",\\n    \"type\": \"text\",\\n    \"page\": 5,\\n    \"field_label\": \"Date: (MM)\",\\n    \"question\": \"What is the month the request was completed?\",\\n    \"context\": \"Month of the date the prior authorization request form was signed by the prescriber.\"\\n  },\\n  {\\n    \"name\": \"T318\",\\n    \"type\": \"text\",\\n    \"page\": 5,\\n    \"field_label\": \"Date: (DD)\",\\n    \"question\": \"What is the day the request was completed?\",\\n    \"context\": \"Day of the date the prior authorization request form was signed by the prescriber.\"\\n  },\\n  {\\n    \"name\": \"T319\",\\n    \"type\": \"text\",\\n    \"page\": 5,\\n    \"field_label\": \"Date: (YYYY)\",\\n    \"question\": \"What is the year the request was completed?\",\\n    \"context\": \"Year of the date the prior authorization request form was signed by the prescriber.\"\\n  }\\n]'}"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "enhanced_pa_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "edc12c95",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Saved enhanced PA fields\n"
     ]
    }
   ],
   "source": [
    "all_pages_data = {}\n",
    "\n",
    "for page_num, json_response in enhanced_pa_data.items():\n",
    "    page_data = json.loads(json_response)\n",
    "    all_pages_data[page_num] = page_data\n",
    "\n",
    "# Save as one pretty JSON file\n",
    "with open(\"pa_all_fields.json\", \"w\") as f:\n",
    "    json.dump(all_pages_data, f, indent=2, ensure_ascii=False)\n",
    "\n",
    "print(f\"Saved enhanced PA fields\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ef6ce149",
   "metadata": {},
   "source": [
    "# MEDICAL DATA"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "8192520b",
   "metadata": {},
   "outputs": [],
   "source": [
    "REFERRAL_PACKAGE_PROMPT = \"\"\"You are an expert medical document processing assistant specializing in Prior Authorization (PA) forms and medical documentation. You are given a list of PA form fields with their associated context and questions. Your task is to thoroughly analyze the provided PDF referral package and extract all relevant information to accurately fill out the PA form.\n",
    "\n",
    "## CRITICAL INSTRUCTIONS:\n",
    "1. **NEVER leave answer fields empty or null** - always provide a specific value\n",
    "2. **For missing information**: Use \"Not documented\" or \"Not specified\" instead of empty strings\n",
    "3. **For checkbox fields**: Always answer with either \"Yes\" or \"No\" (never true/false or empty)\n",
    "4. **For text fields**: Provide the exact information or \"Not available\" if truly missing\n",
    "5. **For dates**: Use MM/DD/YYYY format (unless format is specified) or \"Not specified\" if date is missing \n",
    "6. **Be thorough**: Review the ENTIRE document multiple times to find all relevant information\n",
    "\n",
    "## DETAILED EXTRACTION GUIDELINES:\n",
    "\n",
    "### Patient Information:\n",
    "- Extract ALL demographic details (name, DOB, address, phone, insurance)\n",
    "- Look for patient information in headers, footers, cover pages, and forms\n",
    "- Check multiple pages for complete contact information\n",
    "\n",
    "### Medical Information:\n",
    "- **Diagnoses**: Extract primary and secondary diagnoses with ICD-10 codes if available\n",
    "- **Medications**: Include exact drug names, strengths, frequencies, routes of administration\n",
    "- **Treatment History**: Look for previous medications tried, dates, outcomes, failures\n",
    "- **Clinical Notes**: Extract relevant symptoms, assessments, lab results\n",
    "- **Provider Details**: Include all prescribing physicians, NPIs, addresses, phone numbers\n",
    "\n",
    "### Administrative Details:\n",
    "- **Insurance**: Member IDs, group numbers, prior authorization numbers\n",
    "- **Facility Information**: Infusion centers, pharmacies, administration locations\n",
    "- **Dates**: Treatment start dates, last treatment dates, prescription dates\n",
    "\n",
    "## ANSWER FORMAT REQUIREMENTS:\n",
    "\n",
    "**For Checkbox Fields (CB prefixes):**\n",
    "- Answer ONLY with \"Yes\" or \"No\" \n",
    "- If unclear, use clinical judgment based on available information\n",
    "- Example: If asking about \"Start of treatment\" and document shows new prescription → \"Yes\"\n",
    "\n",
    "**For Text Fields (T prefixes):**\n",
    "- Provide exact values from the document\n",
    "- For dates: Use MM/DD/YYYY format (e.g., \"05/22/2024\") unless format is specified \n",
    "- For names: Use exact spelling and format from document\n",
    "- For missing info: Use \"Not documented\" instead of leaving blank\n",
    "\n",
    "**For Yes/No Questions:**\n",
    "- Base answers on clinical evidence in the document\n",
    "- If patient has the condition/medication/history mentioned → \"Yes\"\n",
    "- If explicitly stated they don't have it or no evidence found → \"No\"\n",
    "\n",
    "## VALIDATION CHECKLIST:\n",
    "Before submitting, ensure:\n",
    "- ✓ Every field has a non-empty answer\n",
    "- ✓ All checkbox answers are \"Yes\" or \"No\"\n",
    "- ✓ All dates follow MM/DD/YYYY format\n",
    "- ✓ Patient demographics are complete\n",
    "- ✓ Medication information is detailed and accurate\n",
    "- ✓ No fields are left with null, empty strings, or boolean values\n",
    "\n",
    "<PA_FORM_DATA>\n",
    "{pa_form_fields}\n",
    "</PA_FORM_DATA>\n",
    "\n",
    "<RESPONSE FORMAT>\n",
    "[\n",
    "  {{\n",
    "    \"name\": \"CB1\",\n",
    "    \"page\": 2,\n",
    "    \"field_label\": \"Start of treatment\",\n",
    "    \"answer\": \"Yes\"\n",
    "  }},\n",
    "  {{\n",
    "    \"name\": \"T2\",\n",
    "    \"page\": 2,\n",
    "    \"field_label\": \"Start date: (MM)\",\n",
    "    \"answer\": \"05\"\n",
    "  }}\n",
    "]\n",
    "</RESPONSE FORMAT>\n",
    "\n",
    "**CRITICAL**: Every field must have a specific answer - no empty strings, no null values, no boolean true/false.\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "id": "07c064b9",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Page 2 completed\n",
      "Page 3 completed\n",
      "Page 4 completed\n",
      "Page 5 completed\n"
     ]
    }
   ],
   "source": [
    "from pydantic import BaseModel, Field, ValidationError\n",
    "from typing import List, Dict, Any\n",
    "import json, re, asyncio, pathlib\n",
    "import google.generativeai as genai\n",
    "\n",
    "# ---------- Schema ----------\n",
    "\n",
    "class PAFormAnswer(BaseModel):\n",
    "    name: str\n",
    "    page: int\n",
    "    field_label: str\n",
    "    answer: str = Field(description=\"answer to the question based on the referral package PDF\")\n",
    "\n",
    "# ---------- Parsing + Validation ----------\n",
    "\n",
    "def _safe_json_loads(text: str) -> Any:\n",
    "    s = text.strip()\n",
    "\n",
    "    # 1) Strip ```json ... ``` or ``` ... ``` fences if present\n",
    "    m = re.search(r\"```(?:json)?\\s*(.*?)\\s*```\", s, re.S | re.I)\n",
    "    if m:\n",
    "        s = m.group(1).strip()\n",
    "\n",
    "    # 2) Keep only outermost JSON array or object if extra prose exists\n",
    "    # Prefer array (your prompt returns a list)\n",
    "    a1, a2 = s.find('['), s.rfind(']')\n",
    "    o1, o2 = s.find('{'), s.rfind('}')\n",
    "    if a1 != -1 and a2 != -1 and a2 > a1:\n",
    "        s = s[a1:a2+1]\n",
    "    elif o1 != -1 and o2 != -1 and o2 > o1:\n",
    "        s = s[o1:o2+1]\n",
    "\n",
    "    return json.loads(s)\n",
    "\n",
    "def parse_and_validate_answers(response_text: str) -> List[PAFormAnswer]:\n",
    "    data = _safe_json_loads(response_text)\n",
    "\n",
    "    # If model returned a single object, wrap into list\n",
    "    if isinstance(data, dict):\n",
    "        data = [data]\n",
    "    if not isinstance(data, list):\n",
    "        raise ValueError(\"Model output is not a JSON array or object.\")\n",
    "\n",
    "    validated: List[PAFormAnswer] = []\n",
    "    for i, item in enumerate(data):\n",
    "        try:\n",
    "            validated.append(PAFormAnswer(**item))\n",
    "        except ValidationError as e:\n",
    "            # Surface which element failed\n",
    "            raise ValueError(f\"Pydantic validation failed at index {i}: {e}\") from e\n",
    "    return validated\n",
    "\n",
    "# ---------- Gemini calls (page-by-page) ----------\n",
    "\n",
    "async def fill_single_page_from_referral(page_num: int,\n",
    "                                         page_fields: list,\n",
    "                                         referral_pdf_path: str,\n",
    "                                         model: str = \"gemini-2.5-flash\"):\n",
    "    prompt = REFERRAL_PACKAGE_PROMPT.format(\n",
    "        pa_form_fields=json.dumps(page_fields, indent=2)\n",
    "    )\n",
    "\n",
    "    loop = asyncio.get_event_loop()\n",
    "\n",
    "    uploaded = await loop.run_in_executor(\n",
    "        None, lambda: genai.upload_file(path=pathlib.Path(referral_pdf_path))\n",
    "    )\n",
    "\n",
    "    response = await loop.run_in_executor(\n",
    "        None,\n",
    "        lambda: genai.GenerativeModel(\n",
    "            model,\n",
    "            generation_config=genai.GenerationConfig(\n",
    "                response_mime_type=\"application/json\"\n",
    "            ),\n",
    "        ).generate_content([uploaded, prompt]),\n",
    "    )\n",
    "\n",
    "    answers = parse_and_validate_answers(response.text)  # robust parse + pydantic\n",
    "    return page_num, [a.model_dump() for a in answers]   # return plain dicts\n",
    "\n",
    "async def fill_pa_pages_sequential(enhanced_fields_by_page: Dict,\n",
    "                                   referral_pdf_path: str,\n",
    "                                   model: str = \"gemini-2.5-flash\"):\n",
    "    # Normalize: allow {field_name: obj} or {page: [fields...]}\n",
    "    first_key = next(iter(enhanced_fields_by_page), None)\n",
    "    if first_key is None:\n",
    "        return {}\n",
    "\n",
    "    if isinstance(enhanced_fields_by_page[first_key], dict):  # looks like field objects\n",
    "        by_page: Dict[int, list] = {}\n",
    "        for f in enhanced_fields_by_page.values():\n",
    "            p = int(f[\"page\"])\n",
    "            by_page.setdefault(p, []).append(f)\n",
    "        enhanced_fields_by_page = by_page\n",
    "\n",
    "    filled_pages: Dict[int, List[Dict[str, Any]]] = {}\n",
    "    for page_num in sorted(enhanced_fields_by_page.keys()):\n",
    "        page_fields = enhanced_fields_by_page[page_num]\n",
    "        page_ret, page_results = await fill_single_page_from_referral(\n",
    "            page_num=page_num,\n",
    "            page_fields=page_fields,\n",
    "            referral_pdf_path=referral_pdf_path,\n",
    "            model=model,\n",
    "        )\n",
    "        filled_pages[page_ret] = page_results\n",
    "        print(f\"Page {page_ret} completed\")\n",
    "\n",
    "    return filled_pages\n",
    "\n",
    "filled_results = await fill_pa_pages_sequential(\n",
    "    enhanced_pa_data,                          # either {page:[...]} or {name: {...}}\n",
    "    \"Input Data/Abdulla/referral_package.pdf\"\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "id": "0d4ac827",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{2: [{'name': 'CB1',\n",
       "   'page': 2,\n",
       "   'field_label': 'Start of treatment',\n",
       "   'answer': 'Yes'},\n",
       "  {'name': 'T2', 'page': 2, 'field_label': 'Start date: (MM)', 'answer': '05'},\n",
       "  {'name': 'T3', 'page': 2, 'field_label': 'Start date: (DD)', 'answer': '22'},\n",
       "  {'name': 'T4',\n",
       "   'page': 2,\n",
       "   'field_label': 'Start date: (YYYY)',\n",
       "   'answer': '2024'},\n",
       "  {'name': 'CB5',\n",
       "   'page': 2,\n",
       "   'field_label': 'Continuation of therapy',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'T6',\n",
       "   'page': 2,\n",
       "   'field_label': 'Date of last treatment: (MM)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T7',\n",
       "   'page': 2,\n",
       "   'field_label': 'Date of last treatment: (DD)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T8',\n",
       "   'page': 2,\n",
       "   'field_label': 'Date of last treatment: (YYYY)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T9',\n",
       "   'page': 2,\n",
       "   'field_label': 'Precertification Requested By:',\n",
       "   'answer': 'Erfan Rostami, BSN, RN'},\n",
       "  {'name': 'T10',\n",
       "   'page': 2,\n",
       "   'field_label': 'Phone:',\n",
       "   'answer': '615-343-1176'},\n",
       "  {'name': 'T11', 'page': 2, 'field_label': 'Fax:', 'answer': '615-343-1219'},\n",
       "  {'name': 'T12',\n",
       "   'page': 2,\n",
       "   'field_label': 'Patient First Name',\n",
       "   'answer': 'Shakh'},\n",
       "  {'name': 'T13',\n",
       "   'page': 2,\n",
       "   'field_label': 'Patient Last Name',\n",
       "   'answer': 'Abdulla'},\n",
       "  {'name': 'T14',\n",
       "   'page': 2,\n",
       "   'field_label': 'Patient DOB (MM/DD/YYYY)',\n",
       "   'answer': '04/01/2001'},\n",
       "  {'name': 'T15',\n",
       "   'page': 2,\n",
       "   'field_label': 'Address:',\n",
       "   'answer': '425 Sherman Ave'},\n",
       "  {'name': 'T16', 'page': 2, 'field_label': 'City:', 'answer': 'Nashville'},\n",
       "  {'name': 'T17', 'page': 2, 'field_label': 'State:', 'answer': 'TN'},\n",
       "  {'name': 'T18', 'page': 2, 'field_label': 'ZIP:', 'answer': '37995'},\n",
       "  {'name': 'T19',\n",
       "   'page': 2,\n",
       "   'field_label': 'Patient Phone',\n",
       "   'answer': '865-395-3958'},\n",
       "  {'name': 'T20',\n",
       "   'page': 2,\n",
       "   'field_label': 'Work Phone:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T21',\n",
       "   'page': 2,\n",
       "   'field_label': 'Cell Phone:',\n",
       "   'answer': '865-395-0481'},\n",
       "  {'name': 'T22',\n",
       "   'page': 2,\n",
       "   'field_label': 'E-mail:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T24', 'page': 2, 'field_label': 'lbs', 'answer': 'Not documented'},\n",
       "  {'name': 'T25', 'page': 2, 'field_label': 'kgs', 'answer': 'Not documented'},\n",
       "  {'name': 'T26',\n",
       "   'page': 2,\n",
       "   'field_label': 'inches',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T27', 'page': 2, 'field_label': 'cms', 'answer': 'Not documented'},\n",
       "  {'name': 'T23',\n",
       "   'page': 2,\n",
       "   'field_label': 'Allergies:',\n",
       "   'answer': 'No Known Allergies'},\n",
       "  {'name': 'T28',\n",
       "   'page': 2,\n",
       "   'field_label': 'Member ID #:',\n",
       "   'answer': 'LAJM14345116'},\n",
       "  {'name': 'T29', 'page': 2, 'field_label': 'Group #:', 'answer': '435000'},\n",
       "  {'name': 'T30',\n",
       "   'page': 2,\n",
       "   'field_label': 'Insured:',\n",
       "   'answer': 'ABDULLA, SHAKH'},\n",
       "  {'name': 'CB31', 'page': 2, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB32', 'page': 2, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'T33',\n",
       "   'page': 2,\n",
       "   'field_label': 'If yes, provide ID#:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T34',\n",
       "   'page': 2,\n",
       "   'field_label': 'Carrier Name:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T35',\n",
       "   'page': 2,\n",
       "   'field_label': 'Insured:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T42', 'page': 2, 'field_label': 'First Name:', 'answer': 'Hao'},\n",
       "  {'name': 'T43', 'page': 2, 'field_label': 'Last Name:', 'answer': 'Gu'},\n",
       "  {'name': 'CB44', 'page': 2, 'field_label': 'M.D.', 'answer': 'Yes'},\n",
       "  {'name': 'CB45', 'page': 2, 'field_label': 'D.O.', 'answer': 'No'},\n",
       "  {'name': 'CB46', 'page': 2, 'field_label': 'N.P.', 'answer': 'No'},\n",
       "  {'name': 'CB47', 'page': 2, 'field_label': 'P.A.', 'answer': 'No'},\n",
       "  {'name': 'T48',\n",
       "   'page': 2,\n",
       "   'field_label': 'Address:',\n",
       "   'answer': '3320 Montgomery Dr.'},\n",
       "  {'name': 'T49', 'page': 2, 'field_label': 'City:', 'answer': 'Nashville'},\n",
       "  {'name': 'T50', 'page': 2, 'field_label': 'State:', 'answer': 'TN'},\n",
       "  {'name': 'T51', 'page': 2, 'field_label': 'ZIP:', 'answer': '37361'},\n",
       "  {'name': 'T52',\n",
       "   'page': 2,\n",
       "   'field_label': 'Phone:',\n",
       "   'answer': '614-936-0065'},\n",
       "  {'name': 'T53', 'page': 2, 'field_label': 'Fax:', 'answer': '615-562-4820'},\n",
       "  {'name': 'T54',\n",
       "   'page': 2,\n",
       "   'field_label': 'St Lic #:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T55', 'page': 2, 'field_label': 'NPI #:', 'answer': '1154611523'},\n",
       "  {'name': 'T56',\n",
       "   'page': 2,\n",
       "   'field_label': 'DEA #:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T57',\n",
       "   'page': 2,\n",
       "   'field_label': 'UPIN:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T58.0',\n",
       "   'page': 2,\n",
       "   'field_label': 'Provider Email:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T58.1',\n",
       "   'page': 2,\n",
       "   'field_label': 'Office Contact Name:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T59',\n",
       "   'page': 2,\n",
       "   'field_label': 'Phone:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'Provider Admin CB.1',\n",
       "   'page': 2,\n",
       "   'field_label': 'Self-administered',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'Provider Admin CB.2',\n",
       "   'page': 2,\n",
       "   'field_label': 'Physician’s Office',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'Provider Admin CB.3',\n",
       "   'page': 2,\n",
       "   'field_label': 'Home',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'Provider Admin CB.4',\n",
       "   'page': 2,\n",
       "   'field_label': 'Outpatient Infusion Center',\n",
       "   'answer': 'Yes'},\n",
       "  {'name': 'Provider Admin T.5',\n",
       "   'page': 2,\n",
       "   'field_label': 'Name:',\n",
       "   'answer': 'Golden Gate Infusion Center'},\n",
       "  {'name': 'Provider Admin CB.7',\n",
       "   'page': 2,\n",
       "   'field_label': 'Home Infusion Center',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'Provider Admin T.6',\n",
       "   'page': 2,\n",
       "   'field_label': 'Phone:',\n",
       "   'answer': 'Not applicable'},\n",
       "  {'name': 'Provider Admin T.8',\n",
       "   'page': 2,\n",
       "   'field_label': 'Agency Name:',\n",
       "   'answer': 'Not applicable'},\n",
       "  {'name': 'Provider Admin CB.10',\n",
       "   'page': 2,\n",
       "   'field_label': 'Administration code(s)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'Provider Admin T.9',\n",
       "   'page': 2,\n",
       "   'field_label': 'CPT:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'Provider Admin T.11A',\n",
       "   'page': 2,\n",
       "   'field_label': 'Address:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'Provider Admin T.13',\n",
       "   'page': 2,\n",
       "   'field_label': 'City:',\n",
       "   'answer': 'Knoxville'},\n",
       "  {'name': 'Provider Admin T.14',\n",
       "   'page': 2,\n",
       "   'field_label': 'State:',\n",
       "   'answer': 'TN'},\n",
       "  {'name': 'Provider Admin T.15',\n",
       "   'page': 2,\n",
       "   'field_label': 'ZIP:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'Provider Admin T.16',\n",
       "   'page': 2,\n",
       "   'field_label': 'Phone:',\n",
       "   'answer': '614-895-7655'},\n",
       "  {'name': 'Provider Admin T.17A',\n",
       "   'page': 2,\n",
       "   'field_label': 'Fax:',\n",
       "   'answer': '614-278-3355'},\n",
       "  {'name': 'Provider Admin T.18',\n",
       "   'page': 2,\n",
       "   'field_label': 'TIN:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'Provider Admin T.19',\n",
       "   'page': 2,\n",
       "   'field_label': 'PIN:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'Provider Admin T.20',\n",
       "   'page': 2,\n",
       "   'field_label': 'NPI:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'Provider Admin CB.21',\n",
       "   'page': 2,\n",
       "   'field_label': 'Outpatient Dialysis Center',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'Provider Admin CB.22',\n",
       "   'page': 2,\n",
       "   'field_label': 'Physician’s Office',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'Provider Admin CB.23.0.0',\n",
       "   'page': 2,\n",
       "   'field_label': 'Retail Pharmacy',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'Provider Admin CB.24.0.0',\n",
       "   'page': 2,\n",
       "   'field_label': 'Specialty Pharmacy',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'Provider Admin CB.25',\n",
       "   'page': 2,\n",
       "   'field_label': 'Mail Order',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'Provider Admin CB.26',\n",
       "   'page': 2,\n",
       "   'field_label': 'Other:',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'Provider Admin T.27',\n",
       "   'page': 2,\n",
       "   'field_label': 'Other:',\n",
       "   'answer': 'Not applicable'},\n",
       "  {'name': 'Provider Admin T.28',\n",
       "   'page': 2,\n",
       "   'field_label': 'Name:',\n",
       "   'answer': 'Golden Gate Infusion Center'},\n",
       "  {'name': 'Provider Admin T.29a',\n",
       "   'page': 2,\n",
       "   'field_label': 'Address:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'Provider Admin T.30a',\n",
       "   'page': 2,\n",
       "   'field_label': 'City:',\n",
       "   'answer': 'Knoxville'},\n",
       "  {'name': 'Provider Admin T.31',\n",
       "   'page': 2,\n",
       "   'field_label': 'State:',\n",
       "   'answer': 'TN'},\n",
       "  {'name': 'Provider Admin T.32',\n",
       "   'page': 2,\n",
       "   'field_label': 'ZIP:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'Provider Admin T.33',\n",
       "   'page': 2,\n",
       "   'field_label': 'Phone:',\n",
       "   'answer': '614-895-7655'},\n",
       "  {'name': 'Provider Admin T.34',\n",
       "   'page': 2,\n",
       "   'field_label': 'Fax:',\n",
       "   'answer': '614-278-3355'},\n",
       "  {'name': 'Provider Admin T.35',\n",
       "   'page': 2,\n",
       "   'field_label': 'TIN:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'Provider Admin T.36',\n",
       "   'page': 2,\n",
       "   'field_label': 'PIN:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'Provider Admin T.37',\n",
       "   'page': 2,\n",
       "   'field_label': 'NPI:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'CB60',\n",
       "   'page': 2,\n",
       "   'field_label': 'Riabni (rituximab-arrx)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB61',\n",
       "   'page': 2,\n",
       "   'field_label': 'Rituxan (rituximab)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB62',\n",
       "   'page': 2,\n",
       "   'field_label': 'Ruxience (rituximab-pvvr)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB63',\n",
       "   'page': 2,\n",
       "   'field_label': 'Truxima (rituximab-abbs)',\n",
       "   'answer': 'Yes'},\n",
       "  {'name': 'T64',\n",
       "   'page': 2,\n",
       "   'field_label': 'Dose:',\n",
       "   'answer': '694 mg (rounded from 693.75 mg = 375 mg/m2 x 1.85 m2 - BSA might be out of date), intraVENOUS'},\n",
       "  {'name': 'T65',\n",
       "   'page': 2,\n",
       "   'field_label': 'Directions for Use:',\n",
       "   'answer': 'Initial Dose: Every 2 weeks, Maintenance Dose: Every 24 weeks. Once, Starting 30 minutes after treatment start time.'},\n",
       "  {'name': 'T66',\n",
       "   'page': 2,\n",
       "   'field_label': 'HCPCS Code:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T67',\n",
       "   'page': 2,\n",
       "   'field_label': 'Primary ICD Code:',\n",
       "   'answer': 'G35'},\n",
       "  {'name': 'CB68',\n",
       "   'page': 2,\n",
       "   'field_label': 'Other ICD Code:',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'T69',\n",
       "   'page': 2,\n",
       "   'field_label': 'Other ICD Code:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'CB70', 'page': 2, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB71', 'page': 2, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB72', 'page': 2, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB73',\n",
       "   'page': 2,\n",
       "   'field_label': 'Ruxience (rituximab-pvvr)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB74',\n",
       "   'page': 2,\n",
       "   'field_label': 'Truxima (rituximab-abbs)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'T75',\n",
       "   'page': 2,\n",
       "   'field_label': 'When was the member’s trial and failure of the preferred drug?',\n",
       "   'answer': 'Not applicable'},\n",
       "  {'name': 'T76',\n",
       "   'page': 2,\n",
       "   'field_label': 'Please describe the nature of the failure of the preferred drug',\n",
       "   'answer': 'Not applicable'},\n",
       "  {'name': 'CB77', 'page': 2, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB78',\n",
       "   'page': 2,\n",
       "   'field_label': 'Ruxience (rituximab-pvvr)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB79',\n",
       "   'page': 2,\n",
       "   'field_label': 'Truxima (rituximab-abbs)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'T80',\n",
       "   'page': 2,\n",
       "   'field_label': 'When was the member’s adverse reaction to the preferred drug?',\n",
       "   'answer': 'Not applicable'},\n",
       "  {'name': 'T81',\n",
       "   'page': 2,\n",
       "   'field_label': 'Please describe the nature of the adverse reaction to the preferred drug',\n",
       "   'answer': 'Not applicable'},\n",
       "  {'name': 'T84',\n",
       "   'page': 2,\n",
       "   'field_label': 'Please explain if there are any contraindications or other medical reason(s) that the patient cannot use any of the following preferred biosimilar products when indicated for the patient’s diagnosis?',\n",
       "   'answer': 'Not applicable'},\n",
       "  {'name': 'CB82',\n",
       "   'page': 2,\n",
       "   'field_label': 'Ruxience (rituximab-pvvr)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB83',\n",
       "   'page': 2,\n",
       "   'field_label': 'Truxima (rituximab-abbs)',\n",
       "   'answer': 'No'}],\n",
       " 3: [{'name': 'T12',\n",
       "   'page': 3,\n",
       "   'field_label': 'Patient First Name',\n",
       "   'answer': 'Shakh'},\n",
       "  {'name': 'T13',\n",
       "   'page': 3,\n",
       "   'field_label': 'Patient Last Name',\n",
       "   'answer': 'Abdulla'},\n",
       "  {'name': 'T19',\n",
       "   'page': 3,\n",
       "   'field_label': 'Patient Phone',\n",
       "   'answer': '865-395-0481'},\n",
       "  {'name': 'T14',\n",
       "   'page': 3,\n",
       "   'field_label': 'Patient DOB (MM/DD/YYYY)',\n",
       "   'answer': '04/01/2001'},\n",
       "  {'name': 'CB86',\n",
       "   'page': 3,\n",
       "   'field_label': 'Inflectra (infliximab-dyyb)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB87',\n",
       "   'page': 3,\n",
       "   'field_label': 'Renflexis (infliximab-abda)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB88',\n",
       "   'page': 3,\n",
       "   'field_label': 'Simponi Aria (golimumab)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'T89',\n",
       "   'page': 3,\n",
       "   'field_label': 'When was the member’s trial and failure of the preferred drug?',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T90',\n",
       "   'page': 3,\n",
       "   'field_label': 'Please describe the nature of the failure of the preferred drug',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'CB85', 'page': 3, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB92',\n",
       "   'page': 3,\n",
       "   'field_label': 'Inflectra (infliximab-dyyb)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB93',\n",
       "   'page': 3,\n",
       "   'field_label': 'Renflexis (infliximab-abda)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB94',\n",
       "   'page': 3,\n",
       "   'field_label': 'Simponi Aria (golimumab)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'T95',\n",
       "   'page': 3,\n",
       "   'field_label': 'When was the member’s adverse reaction to the preferred drug?',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T96a',\n",
       "   'page': 3,\n",
       "   'field_label': 'Please describe the nature of the adverse reaction to the preferred drug',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'CB91', 'page': 3, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB98a',\n",
       "   'page': 3,\n",
       "   'field_label': 'Enbrel (etanercept)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB99a',\n",
       "   'page': 3,\n",
       "   'field_label': 'Humira (adalimumab)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB100a',\n",
       "   'page': 3,\n",
       "   'field_label': 'Idacio (adalimumab-aacf)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB101a',\n",
       "   'page': 3,\n",
       "   'field_label': 'Rinvoq (upadacitinib)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB102a',\n",
       "   'page': 3,\n",
       "   'field_label': 'Tyenne SC (tocilizumab-aazg)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB103a',\n",
       "   'page': 3,\n",
       "   'field_label': 'Xeljanz/Xeljanz XR (tofacitinib)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'T104',\n",
       "   'page': 3,\n",
       "   'field_label': 'When was the member’s trial and failure of the preferred drug?',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T105',\n",
       "   'page': 3,\n",
       "   'field_label': 'Please describe the nature of the failure of the preferred drug',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'CB97', 'page': 3, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB107z',\n",
       "   'page': 3,\n",
       "   'field_label': 'Enbrel (etanercept)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB108z',\n",
       "   'page': 3,\n",
       "   'field_label': 'Humira (adalimumab)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB109z',\n",
       "   'page': 3,\n",
       "   'field_label': 'Idacio (adalimumab-aacf)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB110z',\n",
       "   'page': 3,\n",
       "   'field_label': 'Rinvoq (upadacitinib)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB111z',\n",
       "   'page': 3,\n",
       "   'field_label': 'Tyenne SC (tocilizumab-aazg)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB112z',\n",
       "   'page': 3,\n",
       "   'field_label': 'Xeljanz/Xeljanz XR (tofacitinib)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'T113',\n",
       "   'page': 3,\n",
       "   'field_label': 'When was the member’s adverse reaction to the preferred drug?',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T114',\n",
       "   'page': 3,\n",
       "   'field_label': 'Please describe the nature of the adverse reaction to the preferred drug',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'CB106z', 'page': 3, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'T118',\n",
       "   'page': 3,\n",
       "   'field_label': 'Please explain if there are any contraindications or other medical reason(s) that the patient cannot use any of the following preferred products when indicated for the patient’s diagnosis?',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'CB115z',\n",
       "   'page': 3,\n",
       "   'field_label': 'Inflectra (infliximab-dyyb)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB116z',\n",
       "   'page': 3,\n",
       "   'field_label': 'Renflexis (infliximab-abda)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB117z',\n",
       "   'page': 3,\n",
       "   'field_label': 'Simponi Aria (golimumab)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'T125',\n",
       "   'page': 3,\n",
       "   'field_label': 'Please explain if there are contraindications or any other medical reason(s) that the patient cannot use any of the following preferred products when indicated for the patient’s diagnosis?',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'CB119z',\n",
       "   'page': 3,\n",
       "   'field_label': 'Enbrel (etanercept)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB120z',\n",
       "   'page': 3,\n",
       "   'field_label': 'Humira (adalimumab)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB121z',\n",
       "   'page': 3,\n",
       "   'field_label': 'Idacio (adalimumab-aacf)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB122z',\n",
       "   'page': 3,\n",
       "   'field_label': 'Rinvoq (upadacitinib)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB123z',\n",
       "   'page': 3,\n",
       "   'field_label': 'Tyenne SC (tocilizumab-aazg)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB124z',\n",
       "   'page': 3,\n",
       "   'field_label': 'Xeljanz/Xeljanz XR (tofacitinib)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB96.4.0', 'page': 3, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB98', 'page': 3, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB99.0', 'page': 3, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB100.0', 'page': 3, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB101.0', 'page': 3, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB102.0', 'page': 3, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB103', 'page': 3, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB104', 'page': 3, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB104a',\n",
       "   'page': 3,\n",
       "   'field_label': 'Wegener granulomatosis',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB104b',\n",
       "   'page': 3,\n",
       "   'field_label': 'Churg-Strauss syndrome',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB104c',\n",
       "   'page': 3,\n",
       "   'field_label': 'microscopic polyangiitis',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB104d',\n",
       "   'page': 3,\n",
       "   'field_label': 'pauci-immune glomerulonephritis',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB105', 'page': 3, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB106', 'page': 3, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB106a', 'page': 3, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB107',\n",
       "   'page': 3,\n",
       "   'field_label': 'pemphigus vulgaris',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB108',\n",
       "   'page': 3,\n",
       "   'field_label': 'pemphigus folliaceus',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB109',\n",
       "   'page': 3,\n",
       "   'field_label': 'bullous pemphigoid',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB110',\n",
       "   'page': 3,\n",
       "   'field_label': 'cicatricial pemphigoid',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB111',\n",
       "   'page': 3,\n",
       "   'field_label': 'epidermolysis bullosa acquisita',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB112',\n",
       "   'page': 3,\n",
       "   'field_label': 'paraneoplastic pemphigus',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB113',\n",
       "   'page': 3,\n",
       "   'field_label': 'None of the above',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB106b', 'page': 3, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB114',\n",
       "   'page': 3,\n",
       "   'field_label': 'AIDS-related B-cell lymphoma',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB115',\n",
       "   'page': 3,\n",
       "   'field_label': 'Burkitt lymphoma',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB116',\n",
       "   'page': 3,\n",
       "   'field_label': 'Diffuse large B-cell lymphoma',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB117',\n",
       "   'page': 3,\n",
       "   'field_label': 'Follicular lymphoma',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB118',\n",
       "   'page': 3,\n",
       "   'field_label': 'Gastric MALT lymphoma',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB119',\n",
       "   'page': 3,\n",
       "   'field_label': 'High-grade B-Cell lymphoma',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB120',\n",
       "   'page': 3,\n",
       "   'field_label': 'Mantle cell lymphoma',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB121',\n",
       "   'page': 3,\n",
       "   'field_label': 'Nodal marginal zone lymphoma',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB122',\n",
       "   'page': 3,\n",
       "   'field_label': 'Nongastric MALT lymphoma',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB123',\n",
       "   'page': 3,\n",
       "   'field_label': 'Primary cutaneous B-cell lymphomas',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB124',\n",
       "   'page': 3,\n",
       "   'field_label': 'Splenic marginal zone lymphoma',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB125', 'page': 3, 'field_label': 'Other:', 'answer': 'No'},\n",
       "  {'name': 'T126',\n",
       "   'page': 3,\n",
       "   'field_label': 'Other:',\n",
       "   'answer': 'Not documented'}],\n",
       " 4: [{'name': 'T12',\n",
       "   'page': 4,\n",
       "   'field_label': 'Patient First Name',\n",
       "   'answer': 'Shakh'},\n",
       "  {'name': 'T13',\n",
       "   'page': 4,\n",
       "   'field_label': 'Patient Last Name',\n",
       "   'answer': 'Abdulla'},\n",
       "  {'name': 'T19',\n",
       "   'page': 4,\n",
       "   'field_label': 'Patient Phone',\n",
       "   'answer': '865-395-0481'},\n",
       "  {'name': 'T14',\n",
       "   'page': 4,\n",
       "   'field_label': 'Patient DOB (MM/DD/YYYY)',\n",
       "   'answer': '04/01/2001'},\n",
       "  {'name': 'CB127', 'page': 4, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB128', 'page': 4, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB129',\n",
       "   'page': 4,\n",
       "   'field_label': 'leptomeningeal metastases from lymphoma',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB130',\n",
       "   'page': 4,\n",
       "   'field_label': 'primary CNS lymphoma',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB131',\n",
       "   'page': 4,\n",
       "   'field_label': 'none of the above',\n",
       "   'answer': 'Yes'},\n",
       "  {'name': 'CB132',\n",
       "   'page': 4,\n",
       "   'field_label': 'chronic lymphocytic leukemia (CLL)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB133',\n",
       "   'page': 4,\n",
       "   'field_label': 'small lymphocytic leukemia',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB134',\n",
       "   'page': 4,\n",
       "   'field_label': 'none of the above',\n",
       "   'answer': 'Yes'},\n",
       "  {'name': 'CB135', 'page': 4, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB136', 'page': 4, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB139', 'page': 4, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB140', 'page': 4, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB144', 'page': 4, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB145', 'page': 4, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB141',\n",
       "   'page': 4,\n",
       "   'field_label': 'relapsed hairy cell leukemia',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB142',\n",
       "   'page': 4,\n",
       "   'field_label': 'refractory hairy cell leukemia',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB143',\n",
       "   'page': 4,\n",
       "   'field_label': 'none of the above',\n",
       "   'answer': 'Yes'},\n",
       "  {'name': 'CB137', 'page': 4, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB146',\n",
       "   'page': 4,\n",
       "   'field_label': 'heart transplant recipient',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB147',\n",
       "   'page': 4,\n",
       "   'field_label': 'other solid organ transplant recipient',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB138', 'page': 4, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB148',\n",
       "   'page': 4,\n",
       "   'field_label': 'Bavencio (avelumab)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB149',\n",
       "   'page': 4,\n",
       "   'field_label': 'Imfinzi (durvalumab)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB150',\n",
       "   'page': 4,\n",
       "   'field_label': 'Keytruda (pembrolizumab)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB151',\n",
       "   'page': 4,\n",
       "   'field_label': 'Opdivo (nivolumab)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB152',\n",
       "   'page': 4,\n",
       "   'field_label': 'Tecentriq (atezolizumab)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB153',\n",
       "   'page': 4,\n",
       "   'field_label': 'Yervoy (ipilimumab)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB154', 'page': 4, 'field_label': 'Other:', 'answer': 'No'},\n",
       "  {'name': 'T155',\n",
       "   'page': 4,\n",
       "   'field_label': 'Other:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'CB156', 'page': 4, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB158',\n",
       "   'page': 4,\n",
       "   'field_label': 'refractory immune thrombocytopenic purpura',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB159',\n",
       "   'page': 4,\n",
       "   'field_label': 'idiopathic thrombocytopenic purpura (ITP)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB157', 'page': 4, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB160', 'page': 4, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB161', 'page': 4, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB162', 'page': 4, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB163', 'page': 4, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB164',\n",
       "   'page': 4,\n",
       "   'field_label': 'Relapsing-remitting MS (RRMS)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB165',\n",
       "   'page': 4,\n",
       "   'field_label': 'Secondary-progressive MS (SPMS)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB166',\n",
       "   'page': 4,\n",
       "   'field_label': 'Primary-progressive MS (PPMS)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB167',\n",
       "   'page': 4,\n",
       "   'field_label': 'Progressive-relapsing MS (PRMS)',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB168', 'page': 4, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB169', 'page': 4, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB170', 'page': 4, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB172', 'page': 4, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB173', 'page': 4, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB171', 'page': 4, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB174', 'page': 4, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB175', 'page': 4, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB176', 'page': 4, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB177', 'page': 4, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB178', 'page': 4, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB179', 'page': 4, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB180', 'page': 4, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'T189',\n",
       "   'page': 4,\n",
       "   'field_label': 'Medication:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T190',\n",
       "   'page': 4,\n",
       "   'field_label': 'Date: (MM)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T191',\n",
       "   'page': 4,\n",
       "   'field_label': 'Date: (DD)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T192',\n",
       "   'page': 4,\n",
       "   'field_label': 'Date: (YYYY)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T193',\n",
       "   'page': 4,\n",
       "   'field_label': 'Date: (MM)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T194',\n",
       "   'page': 4,\n",
       "   'field_label': 'Date: (DD)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T195',\n",
       "   'page': 4,\n",
       "   'field_label': 'Date: (YYYY)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T196',\n",
       "   'page': 4,\n",
       "   'field_label': 'Medication:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T197',\n",
       "   'page': 4,\n",
       "   'field_label': 'Date: (MM)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T198',\n",
       "   'page': 4,\n",
       "   'field_label': 'Date: (DD)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T199',\n",
       "   'page': 4,\n",
       "   'field_label': 'Date: (YYYY)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T200',\n",
       "   'page': 4,\n",
       "   'field_label': 'Date: (MM)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T201',\n",
       "   'page': 4,\n",
       "   'field_label': 'Date: (DD)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T202',\n",
       "   'page': 4,\n",
       "   'field_label': 'Date: (YYYY)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'CB181', 'page': 4, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB203', 'page': 4, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB204', 'page': 4, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB205', 'page': 4, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB206', 'page': 4, 'field_label': 'No', 'answer': 'Yes'}],\n",
       " 5: [{'name': 'T12',\n",
       "   'page': 5,\n",
       "   'field_label': 'Patient First Name',\n",
       "   'answer': 'Shakh'},\n",
       "  {'name': 'T13',\n",
       "   'page': 5,\n",
       "   'field_label': 'Patient Last Name',\n",
       "   'answer': 'Abdulla'},\n",
       "  {'name': 'T19',\n",
       "   'page': 5,\n",
       "   'field_label': 'Patient Phone',\n",
       "   'answer': '865-395-0481'},\n",
       "  {'name': 'T14',\n",
       "   'page': 5,\n",
       "   'field_label': 'Patient DOB (MM/DD/YYYY)',\n",
       "   'answer': '04/01/2001'},\n",
       "  {'name': 'CB207', 'page': 5, 'field_label': 'Mild', 'answer': 'No'},\n",
       "  {'name': 'CB208', 'page': 5, 'field_label': 'Moderate', 'answer': 'No'},\n",
       "  {'name': 'CB209', 'page': 5, 'field_label': 'Severe', 'answer': 'No'},\n",
       "  {'name': 'CB210', 'page': 5, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB211', 'page': 5, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB212', 'page': 5, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB213', 'page': 5, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB214', 'page': 5, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB216', 'page': 5, 'field_label': 'ineffective', 'answer': 'No'},\n",
       "  {'name': 'CB217', 'page': 5, 'field_label': 'not tolerated', 'answer': 'No'},\n",
       "  {'name': 'CB218',\n",
       "   'page': 5,\n",
       "   'field_label': 'contraindicated',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB215', 'page': 5, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB223', 'page': 5, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB225', 'page': 5, 'field_label': 'azathioprine', 'answer': 'No'},\n",
       "  {'name': 'CB226', 'page': 5, 'field_label': 'cyclosporine', 'answer': 'No'},\n",
       "  {'name': 'CB227',\n",
       "   'page': 5,\n",
       "   'field_label': 'hydroxychloroquine',\n",
       "   'answer': 'No'},\n",
       "  {'name': 'CB228', 'page': 5, 'field_label': 'leflunomide', 'answer': 'No'},\n",
       "  {'name': 'CB229', 'page': 5, 'field_label': 'sulfasalazine', 'answer': 'No'},\n",
       "  {'name': 'CB224', 'page': 5, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB281', 'page': 5, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB282', 'page': 5, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB283', 'page': 5, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'T285',\n",
       "   'page': 5,\n",
       "   'field_label': 'Medication:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T286',\n",
       "   'page': 5,\n",
       "   'field_label': 'Date: (MM)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T287',\n",
       "   'page': 5,\n",
       "   'field_label': 'Date: (DD)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T288',\n",
       "   'page': 5,\n",
       "   'field_label': 'Date: (YYYY)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T289',\n",
       "   'page': 5,\n",
       "   'field_label': 'Date: (MM)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T290',\n",
       "   'page': 5,\n",
       "   'field_label': 'Date: (DD)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T291',\n",
       "   'page': 5,\n",
       "   'field_label': 'Date: (YYYY)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T292',\n",
       "   'page': 5,\n",
       "   'field_label': 'Medication:',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T293',\n",
       "   'page': 5,\n",
       "   'field_label': 'Date: (MM)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T294',\n",
       "   'page': 5,\n",
       "   'field_label': 'Date: (DD)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T295',\n",
       "   'page': 5,\n",
       "   'field_label': 'Date: (YYYY)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T296',\n",
       "   'page': 5,\n",
       "   'field_label': 'Date: (MM)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T297',\n",
       "   'page': 5,\n",
       "   'field_label': 'Date: (DD)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'T298',\n",
       "   'page': 5,\n",
       "   'field_label': 'Date: (YYYY)',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'CB284', 'page': 5, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB299', 'page': 5, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB300', 'page': 5, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB301', 'page': 5, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB302', 'page': 5, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB303', 'page': 5, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB304', 'page': 5, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'T305',\n",
       "   'page': 5,\n",
       "   'field_label': 'Please indicate the length of time on Rituxan (rituximab):',\n",
       "   'answer': 'Not documented'},\n",
       "  {'name': 'CB310', 'page': 5, 'field_label': 'Mild', 'answer': 'No'},\n",
       "  {'name': 'CB311', 'page': 5, 'field_label': 'Moderate', 'answer': 'No'},\n",
       "  {'name': 'CB312', 'page': 5, 'field_label': 'Severe', 'answer': 'No'},\n",
       "  {'name': 'CB306', 'page': 5, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB307', 'page': 5, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB308', 'page': 5, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB309', 'page': 5, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB313', 'page': 5, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB314', 'page': 5, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'CB315', 'page': 5, 'field_label': 'Yes', 'answer': 'No'},\n",
       "  {'name': 'CB316', 'page': 5, 'field_label': 'No', 'answer': 'Yes'},\n",
       "  {'name': 'T317', 'page': 5, 'field_label': 'Date: (MM)', 'answer': '05'},\n",
       "  {'name': 'T318', 'page': 5, 'field_label': 'Date: (DD)', 'answer': '22'},\n",
       "  {'name': 'T319',\n",
       "   'page': 5,\n",
       "   'field_label': 'Date: (YYYY)',\n",
       "   'answer': '2024'}]}"
      ]
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "filled_results"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "id": "03d7976e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total fields: 335\n",
      "Answered: 263\n",
      "Not documented: 72\n",
      "Answered %: 78.51%\n",
      "Not documented %: 21.49%\n"
     ]
    }
   ],
   "source": [
    "# Count answers across all pages\n",
    "total_fields = 0\n",
    "answered = 0\n",
    "not_documented = 0\n",
    "\n",
    "for page_fields in filled_results.values():\n",
    "    for field in page_fields:\n",
    "        total_fields += 1\n",
    "        if field[\"answer\"].strip().lower() in [\"not documented\", \"not specified\", \"not available\"]:\n",
    "            not_documented += 1\n",
    "        else:\n",
    "            answered += 1\n",
    "\n",
    "print(f\"Total fields: {total_fields}\")\n",
    "print(f\"Answered: {answered}\")\n",
    "print(f\"Not documented: {not_documented}\")\n",
    "print(f\"Answered %: {answered/total_fields*100:.2f}%\")\n",
    "print(f\"Not documented %: {not_documented/total_fields*100:.2f}%\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "id": "6fabe837",
   "metadata": {},
   "outputs": [],
   "source": [
    "import fitz  # PyMuPDF\n",
    "from pathlib import Path\n",
    "\n",
    "def build_answer_index(filled_results: dict) -> dict:\n",
    "    \"\"\"\n",
    "    filled_results: {page_num: [ {name, page, field_label, answer}, ...], ...}\n",
    "    returns: {field_name: answer}\n",
    "    \"\"\"\n",
    "    idx = {}\n",
    "    for page, items in filled_results.items():\n",
    "        for it in items:\n",
    "            name = str(it.get(\"name\", \"\")).strip()\n",
    "            if not name:\n",
    "                continue\n",
    "            idx[name] = str(it.get(\"answer\", \"\")).strip()\n",
    "    return idx\n",
    "\n",
    "def _bool_from_yes_no(s: str) -> bool:\n",
    "    return str(s).strip().lower() in (\"yes\", \"y\", \"true\", \"checked\", \"on\", \"1\")\n",
    "\n",
    "def fill_pa_pdf_from_answers(\n",
    "    pa_pdf_in: str,\n",
    "    filled_results: dict,\n",
    "    out_pdf: str = None,\n",
    "    make_flattened_copy: bool = False\n",
    ") -> str:\n",
    "    \"\"\"\n",
    "    Fills the PDF fields using answers. Returns the path to the filled PDF.\n",
    "    - pa_pdf_in: path to the original PA PDF\n",
    "    - filled_results: your dict keyed by page number with answer dicts\n",
    "    - out_pdf: optional output path; defaults to '<name>_filled.pdf'\n",
    "    - make_flattened_copy: also write a '<name>_filled_flat.pdf' (basic flatten)\n",
    "    \"\"\"\n",
    "    pa_pdf_in = str(pa_pdf_in)\n",
    "    out_pdf = out_pdf or str(Path(pa_pdf_in).with_name(Path(pa_pdf_in).stem + \"_filled.pdf\"))\n",
    "\n",
    "    answers_by_name = build_answer_index(filled_results)\n",
    "\n",
    "    doc = fitz.open(pa_pdf_in)\n",
    "    filled = 0\n",
    "    missing = []\n",
    "\n",
    "    for page in doc:  # iterate pages\n",
    "        widgets = page.widgets() or []\n",
    "        for w in widgets:\n",
    "            fname = w.field_name or \"\"\n",
    "            if not fname:\n",
    "                continue\n",
    "            if fname not in answers_by_name:\n",
    "                missing.append(fname)\n",
    "                continue\n",
    "\n",
    "            ans = answers_by_name[fname]\n",
    "\n",
    "            try:\n",
    "                # Checkbox\n",
    "                if w.field_type == fitz.PDF_WIDGET_TYPE_CHECKBOX:\n",
    "                    checked = _bool_from_yes_no(ans)\n",
    "                    # Primary way: set On/Off value and update appearance\n",
    "                    w.field_value = \"Yes\" if checked else \"Off\"\n",
    "                    w.update()\n",
    "                    filled += 1\n",
    "                else:\n",
    "                    # Text / other entry\n",
    "                    w.field_value = ans\n",
    "                    w.update()\n",
    "                    filled += 1\n",
    "            except Exception:\n",
    "                # Fallbacks for odd PDFs\n",
    "                try:\n",
    "                    if w.field_type == fitz.PDF_WIDGET_TYPE_CHECKBOX:\n",
    "                        # Some versions expose a button_set helper\n",
    "                        w.button_set(_bool_from_yes_no(ans))\n",
    "                    else:\n",
    "                        w.set_value(str(ans))\n",
    "                    w.update()\n",
    "                    filled += 1\n",
    "                except Exception as e:\n",
    "                    print(f\"Could not write field '{fname}': {e}\")\n",
    "\n",
    "    # Save the filled, editable form\n",
    "    doc.save(out_pdf, deflate=True)\n",
    "    doc.close()\n",
    "\n",
    "    print(f\"Filled {filled} widgets. Missing answers for {len(missing)} fields.\")\n",
    "    if missing:\n",
    "        # optional: inspect a few missing names to refine mapping\n",
    "        print(\"Examples of fields with no answer:\", missing[:10])\n",
    "\n",
    "    # (Optional) basic flatten: reopen and save with cleaning / appearance streams kept\n",
    "    if make_flattened_copy:\n",
    "        flat_path = str(Path(out_pdf).with_name(Path(out_pdf).stem + \"_flat.pdf\"))\n",
    "        d2 = fitz.open(out_pdf)\n",
    "        # This \"flatten\" keeps appearances and removes form editing.\n",
    "        # (True, full flattening can be more involved across PDFs, but this works for most.)\n",
    "        d2.save(flat_path, deflate=True, garbage=4, clean=True)\n",
    "        d2.close()\n",
    "        print(f\"Flattened copy written to: {flat_path}\")\n",
    "\n",
    "    return out_pdf\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "id": "bf5cefc9",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "MuPDF error: format error: partial block in aes filter\n",
      "\n",
      "Filled 335 widgets. Missing answers for 0 fields.\n",
      "Flattened copy written to: Input Data/Abdulla/PA_filled_flat.pdf\n",
      "Saved: Input Data/Abdulla/PA_filled.pdf\n"
     ]
    }
   ],
   "source": [
    "filled_pdf_path = fill_pa_pdf_from_answers(\n",
    "    pa_pdf_in=\"Input Data/Abdulla/PA.pdf\",\n",
    "    filled_results=filled_results,   \n",
    "    out_pdf=\"Input Data/Abdulla/PA_filled.pdf\",\n",
    "    make_flattened_copy=True         \n",
    ")\n",
    "print(\"Saved:\", filled_pdf_path) # open it with Adobe \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c9acf731",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.13"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
